---
title: "Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Clinical evidence"
description: "Formulary evidence on Darovasertib (IDE196, LXS196) in First-line metastatic uveal melanoma, in combination with crizotinib: Clinical evidence. Covers OptimUM-02, OptimUM-01, and CLXS196X2101. 225 evidence topics quoted from 31 sources."
canonical: "https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/clinical-evidence"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Clinical evidence

<a id="clinical-evidence"></a>

## 3 Clinical Evidence

<a id="heading-3.1"></a>

### 3.1 Study Summaries

<a id="heading-3.1.1"></a>

#### 3.1.1 OptimUM-02

<a id="heading-3.1.1.1"></a>

##### 3.1.1.1 Objective

<a id="topic-3.1.1.1-1"></a>

###### Study purpose in the ClinicalTrials.gov record

> “This study is designed as a multi-stage Phase 2 study within a Phase 3 study to evaluate the safety, tolerability, pharmacokinetics, dose-exposure relationship, and anti-tumor activity of IDE196 in combination with crizotinib compared to the comparator arm of investigator's choice of treatment (pembrolizumab, ipilimumab + nivolumab, or dacarbazine).”

Source: [ClinicalTrials.gov NCT05987332](https://clinicaltrials.gov/study/NCT05987332)

<a id="topic-3.1.1.1-2"></a>

###### Phase 2a, phase 2b, and phase 3 objectives in the EU trial record

> “Phase 2a: To determine the optimal dose of IDE196 + crizotinib combination in Phase 2a in order to establish the recommended dose for Phase 2b and Phase 3”
> “Phase 2b: To compare IDE196 + crizotinib to investigator’s choice of treatment with respect to PFS per RECIST 1.1 as assessed by blinded independent central review (BICR)”
> “Phase 3:To compare IDE196 + crizotinib to investigator’s choice of treatment with respect to OS”

Source: [EU CTIS 2023-506686-66-01](https://euclinicaltrials.eu/ctis-public-api/retrieve/2023-506686-66-01)

<a id="topic-3.1.1.1-3"></a>

###### Secondary objectives in the EU trial record

> “Phase 3, Options 1 and 2: To compare IDE196 + crizotinib to investigator’s choice of treatment with respect to objective response rate (ORR) per RECIST v1.1 as assessed by BICR”
> “Phase 3, Option 3: To compare IDE196 + crizotinib to investigator’s choice of treatment with respect to PFS and ORR per RECIST v1.1 as assessed by BICR”
> “To evaluate the safety and tolerability of IDE196 in combination with crizotinib”
> “To compare IDE196 + crizotinib to investigator’s choice of treatment with respect to PFS per RECIST v1.1 as assessed by investigator”
> “To compare IDE196 + crizotinib to investigator’s choice of treatment with respect to objective response and DOR per RECIST v1.1 as assessed by investigator”
> “To compare IDE196 + crizotinib to investigator’s choice of treatment with respect to quality-of-life scores.”

Source: [EU CTIS 2023-506686-66-01](https://euclinicaltrials.eu/ctis-public-api/retrieve/2023-506686-66-01)

<a id="topic-3.1.1.1-4"></a>

###### Aim of the primary analysis in the ASCO 2026 abstract

> “Here we present primary safety & efficacy results from the nested phase 2/3 OptimUM-02 trial of darova+crizo as first-line treatment for HLA-A2 negative-mUM.”

Source: [Orloff et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO.2026.44.17_suppl.LBA9503)

<a id="topic-3.1.1.1-5"></a>

###### Aim of the subgroup analysis in the ESMO 2026 poster

> “Here, we present efficacy results from OptimUM-02 across subgroups defined by key baseline characteristics, including historically difficult to treat populations (e.g., high baseline LDH, extra-hepatic disease, or large lesions)”
> “Results were also compared with findings from the OptimUM-01 trial to assess consistency of response across studies”

Source: [Piperno-Neumann et al. (2026c)](https://www.ideayabio.com/sites/default/files/publications/2026-11/ESMO-2026-Piperno-Neumann-OptimUM-02.pdf)

<a id="heading-3.1.1.2"></a>

##### 3.1.1.2 Location and Study Date

<a id="topic-3.1.1.2-1"></a>

###### Study status, dates, and number of sites in the ClinicalTrials.gov record

| Study characteristic | Quoted record |
| --- | --- |
| Overall status | “Active, not recruiting” |
| Study start (actual) | “2023-10-31” |
| Primary completion (estimated) | “2027-01-15” |
| Study completion (estimated) | “2028-01-15” |
| Sites | “This study has 68 locations” |
| Last update posted | “Last Update Posted 2026-02-17” |

Source: [ClinicalTrials.gov NCT05987332](https://clinicaltrials.gov/study/NCT05987332)

<a id="topic-3.1.1.2-2"></a>

###### Countries with listed sites in the ClinicalTrials.gov record

| Country | Example of a listed site location |
| --- | --- |
| United States | “Philadelphia, Pennsylvania, United States, 19107” |
| Australia | “Melbourne, Victoria, Australia, 3000” |
| Belgium | “Brussels, Belgium, 1200” |
| Canada | “Toronto, Ontario, Canada, M5G 2M9” |
| France | “Paris, France, 75005” |
| Germany | “Heidelberg, Baden-Wurttemberg, Germany, 69120” |
| Israel | “Jerusalem, Israel, 91120” |
| Italy | “Milan, Italy, 20133” |
| Netherlands | “Leiden, Netherlands, 2333 ZA” |
| Poland | “Warsaw, Poland, 02-781” |
| Spain | “Madrid, Spain, 28046” |
| Switzerland | “Zurich, Switzerland, 8058” |
| United Kingdom | “Glasgow, United Kingdom, G12 0YN” |

Source: [ClinicalTrials.gov NCT05987332](https://clinicaltrials.gov/study/NCT05987332)

<a id="topic-3.1.1.2-3"></a>

###### European Union dates in the EU trial record

| Field | Quoted record |
| --- | --- |
| Start date in the European Union | “2024-10-09” |
| Estimated recruitment start date | “2024-07-01” |
| Estimated global end date | “2027-12-31” |

Source: [EU CTIS 2023-506686-66-01](https://euclinicaltrials.eu/ctis-public-api/retrieve/2023-506686-66-01)

<a id="topic-3.1.1.2-4"></a>

###### Enrollment progress in December 2024

> “Over 185 patients enrolled in potential registration-enabling trial in 1L HLA-A2-Negative MUM, and the darovasertib and crizotinib combination has received U.S. Food and Drug Administration (FDA) Fast Track designation in MUM”

Source: [IDEAYA Biosciences press release, IDMC move-forward dose recommendation (2024)](https://media.ideayabio.com/2024-12-17-IDEAYA-Announces-IDMC-Recommendation-of-Move-Forward-Dose-in-Part-2a-of-Registration-Enabling-Trial-of-Darovasertib-and-Crizotinib-Combination-in-1L-HLA-A2-Negative-Metastatic-Uveal-Melanoma)

<a id="topic-3.1.1.2-5"></a>

###### Enrollment progress and international sites as of February 2025

> “We have enrolled over 230 patients as of February 7, 2025, and have opened multiple clinical sites, including international sites, in our potential registration-enabling Phase 2/3 clinical trial, designated as IDE196-002.”

Source: [IDEAYA Biosciences Form 10-K (2025)](https://www.sec.gov/Archives/edgar/data/1676725/000095017025022183/idya-20241231.htm)

<a id="topic-3.1.1.2-6"></a>

###### Data cutoff of the primary analysis presented at ASCO 2026

> “Data presented at ASCO were as of a cutoff date of January 23, 2026 and included additional detail on baseline characteristics as well as safety, secondary endpoints and median PFS across patient subgroups.”
> “The data were provided in a late-breaking oral presentation by Dr. Marlana Orloff, M.D., Professor of Medical Oncology at Thomas Jefferson University Hospital and lead investigator on the trial.”

Source: [IDEAYA Biosciences press release, OptimUM-02 ASCO 2026 data (2026)](https://media.ideayabio.com/2026-06-01-IDEAYA-Biosciences-and-Servier-Provide-Complete-Data-from-Phase-2-3-Registrational-OptimUM-02-Trial-of-the-Darovasertib-Combination-in-First-Line-HLA-A2-01-Negative-Metastatic-Uveal-Melanoma-in-a-Late-Breaking-Oral-Presentation-at-ASCO)

<a id="topic-3.1.1.2-7"></a>

###### Subgroup analysis presented at ESMO 2026

> “Presented at the 2026 ESMO Congress, October 23–27, 2026 Madrid, Spain.”

Source: [Piperno-Neumann et al. (2026c)](https://www.ideayabio.com/sites/default/files/publications/2026-11/ESMO-2026-Piperno-Neumann-OptimUM-02.pdf)

<a id="heading-3.1.1.3"></a>

##### 3.1.1.3 Study Design

<a id="topic-3.1.1.3-1"></a>

###### Multi-stage randomized open-label design in the ClinicalTrials.gov record

> “This is a Phase 2/3, multi-arm, multi-stage, open-label study of human leukocyte antigen (HLA)-A*02:01 negative participants with metastatic uveal melanoma (MUM) who will be randomized to receive either IDE196 + crizotinib or investigator's choice of treatment (pembrolizumab, ipilimumab + nivolumab, or dacarbazine).”
> “The Phase 2a dose optimization stage will evaluate two doses of IDE196 in combination with crizotinib compared to the comparator arm. Participants will be randomized to the three treatment arms. At the point of optimal IDE196 + crizotinib dose selection, the other dose arm will be dropped with discontinuation of enrollment to that arm. Participants receiving the IDE196 dose (in combination with crizotinib) that is not selected, will be offered the choice to remain on the same dose or change to the chosen optimal dose.”
> “The optimal dose will be chosen to complete the Phase 2b portion. The Phase 2b part of the study will continue to enroll the chosen combination dose of IDE196 + crizotinib compared with the comparator arm. Participants will be randomized to the two treatment arms.”
> “The Phase 3 part of the study will continue to enroll the chosen combination dose of IDE196 + crizotinib compared with the comparator arm. Participants will be randomized to the two treatment arms to evaluate the primary endpoint of overall survival (OS).”

Source: [ClinicalTrials.gov NCT05987332](https://clinicaltrials.gov/study/NCT05987332)

<a id="topic-3.1.1.3-2"></a>

###### Allocation, assignment model, and masking in the ClinicalTrials.gov record

| Design characteristic | Quoted record |
| --- | --- |
| Allocation | “Randomized” |
| Interventional model | “Sequential Assignment” |
| Masking | “None (Open Label)” |

Source: [ClinicalTrials.gov NCT05987332](https://clinicaltrials.gov/study/NCT05987332)

<a id="topic-3.1.1.3-3"></a>

###### Randomization ratios and stratification factors in the ASCO 2026 presentation

> “Phase 2/3, multi-center, multi-arm, multi-stage, open-label study”
> “Patients will be stratified by baseline LDH (≤ULN vs >ULN, but less than 2-fold the ULN vs ≥ 2-fold the ULN) and investigator’s choice of comparator treatment (ipilimumab + nivolumab vs single-agent therapy).”

Source: [Orloff et al. (2026a)](https://filecache.investorroom.com/mr5ir_ideayabio/616/OptimUM-02%20ASCO%20-%2026MAY2026.pdf)

| Study stage | Randomization ratio shown in the study design figure |
| --- | --- |
| Phase 2a (darovasertib 300 mg BID plus crizotinib, darovasertib 200 mg BID plus crizotinib, investigator's choice) | “2:2:1” |
| Phase 2b and phase 3 (darovasertib 300 mg BID plus crizotinib, investigator's choice) | “2:1” |

Source: [Orloff et al. (2026a)](https://filecache.investorroom.com/mr5ir_ideayabio/616/OptimUM-02%20ASCO%20-%2026MAY2026.pdf)

<a id="topic-3.1.1.3-4"></a>

###### Randomization of first-line HLA-A2-negative participants in the ASCO 2026 abstract

> “OptimUM-02 is an open-label study of HLA-A2 negative first-line mUM patients who were randomized 2:1 to receive darova 300 mg plus crizo 200 mg BID or investigator’s choice (IC) of treatment (pembrolizumab, ipilimumab + nivolumab, or dacarbazine).”

Source: [Orloff et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO.2026.44.17_suppl.LBA9503)

<a id="topic-3.1.1.3-5"></a>

###### Random assignment in the phase 2b and phase 3 portions as reported from the ASCO 2026 presentation

> “In the phase IIb and phase III portions, patients were randomly assigned 2:1 to receive darovasertib at 300 mg twice-daily plus crizotinib at 200 mg twice-daily or investigator’s choice of pembrolizumab, ipilimumab/nivolumab, or dacarbazine.”

Source: [Barbor (2026)](https://ascopost.com/articles/2026/08-august/darovasertib-plus-crizotinib-may-set-new-first-line-standard-in-hla-a2-negative-metastatic-uveal-melanoma/)

<a id="topic-3.1.1.3-6"></a>

###### Integrated study-in-study design after the FDA Type C meeting, April 2023

> “The protocol includes an integrated Phase 2/3 open-label study-in-study design in first-line MUM patients with an HLA-A*02:01 negative serotype.”
> “The treatment arm of the Phase 2 portion includes a nested study to confirm the move forward combination dose for the integrated Phase 2/3 clinical trial – including cohorts at the Phase 2 expansion doses of (i) darovasertib 300 mg BID + crizotinib 200 mg BID and (ii) darovasertib 200 mg BID + crizotinib 200 mg BID.”
> “Under the nested study design, patients enrolled in the cohort at the move forward dose will be included within the Phase 2/3 registrational clinical trial.”

Source: [IDEAYA Biosciences press release, FDA Type C meeting and interim phase 2 data (2023)](https://media.ideayabio.com/2023-04-23-IDEAYA-Announces-Positive-Interim-Phase-2-Data-for-Darovasertib-and-Crizotinib-Combination-and-Successful-FDA-Type-C-Meeting-on-Registrational-Trial-Design-for-Accelerated-Approval-in-First-Line-Metastatic-Uveal-Melanoma)

<a id="topic-3.1.1.3-7"></a>

###### Completion of phase 2a dose optimization on an independent data monitoring committee recommendation, December 2024

> “Independent Data Monitoring Committee (IDMC) recommends move-forward dose in Part 2a of potential registration-enabling trial in 1L HLA-A2-Negative MUM, based on clinical efficacy and safety observed”
> “SAN FRANCISCO, Dec. 17, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced the Independent Data Monitoring Committee (IDMC) recommendation of a move-forward dose and the completion of the Part 2a dose optimization consistent with the U.S. Food and Drug Administration's (FDA) Project Optimus guidelines for the potential registration-enabling Phase 2/3 trial evaluating the combination of darovasertib and crizotinib in the first-line (1L) setting in patients with HLA-A2-negative (HLA-A2(-)) metastatic uveal melanoma (MUM).”

Source: [IDEAYA Biosciences press release, IDMC move-forward dose recommendation (2024)](https://media.ideayabio.com/2024-12-17-IDEAYA-Announces-IDMC-Recommendation-of-Move-Forward-Dose-in-Part-2a-of-Registration-Enabling-Trial-of-Darovasertib-and-Crizotinib-Combination-in-1L-HLA-A2-Negative-Metastatic-Uveal-Melanoma)

<a id="topic-3.1.1.3-8"></a>

###### Crossover from the control arm

No evidence found.

<a id="heading-3.1.1.4"></a>

##### 3.1.1.4 Eligibility Criteria

<a id="topic-3.1.1.4-1"></a>

###### Inclusion criteria in the ClinicalTrials.gov record

| Inclusion criterion | Quoted record |
| --- | --- |
| Diagnosis | “Histological or cytological confirmed Metastatic Uveal Melanoma” |
| HLA type required | “HLA-A*02:01 negative” |
| Prior therapy | “No prior systemic therapy in the metastatic or advanced setting regional or liver-directed therapy. Ablations or surgical resection of oligometastatic disease, and neoadjuvant or adjuvant therapy is allowed” |
| Measurable disease | “Measurable disease per RECIST 1.1” |
| Ability to take study therapy | “Able to be safely administered and absorb study therapy” |
| Performance status | “ECOG performance status 0 or 1” |
| Life expectancy | “Life expectancy of ≥3 months” |
| Organ function | “Adequate organ function” |
| Ages eligible | “18 Years and older (Adult,  Older Adult )” |

Source: [ClinicalTrials.gov NCT05987332](https://clinicaltrials.gov/study/NCT05987332)

<a id="topic-3.1.1.4-2"></a>

###### Exclusion criteria in the ClinicalTrials.gov record

> “Previous treatment with a PKC inhibitor (including prior treatment with IDE196), an inhibitor directly targeting MET, or an inhibitor directly targeting GNAQ/11”
> “AEs from prior anti-cancer therapy that have not resolved to Grade ≤1”
> “Symptomatic or untreated central nervous system (CNS) metastases, or CNS metastases that require corticosteroids”
> “High risk of syncope or falls”
> “Active adrenal insufficiency, active colitis, or active inflammatory bowel disease”
> “History of interstitial lung disease, active pneumonitis, or history of pneumonitis requiring steroids”
> “Active infection requiring systemic antibiotic therapy or active Hepatitis B/C”
> “Major surgery, radiotherapy, or use of hematopoietic colony-stimulating factors (CSF) within 2 weeks prior to start of study drug”
> “Females who are pregnant or breastfeeding”
> “History of severe hypersensitivity reactions (eg, anaphylaxis) to other biologic drugs or monoclonal antibodies”
> “Contraindication for treatment with investigator's choice therapies as per applicable labelling”
> “History of stroke within the last 6 months of the first dose of study drug”
> “Impaired Cardiac function or clinically significant cardiac diseases, including angina pectoris or acute myocardial infarction <= 6 months prior to start of study treatment”

Source: [ClinicalTrials.gov NCT05987332](https://clinicaltrials.gov/study/NCT05987332)

<a id="topic-3.1.1.4-3"></a>

###### Prior treatment requirements in the EU trial record

> “No prior systemic therapy in the metastatic or advanced setting including chemotherapy, immunotherapy, or targeted therapy”
> “No prior regional, liver-directed therapy including chemotherapy, radiotherapy, or embolization”
> “Prior ablations or surgical resection of oligometastatic disease are allowed”
> “Prior neoadjuvant or adjuvant therapy is allowed provided administered in the curative setting in participants with localized disease and a minimum of 4 weeks (28 days) has elapsed since the end of neoadjuvant/adjuvant treatment and the start of study treatment”
> “Participants who have received a combination of anti-programmed cell death ligand 1 (PD-L1) plus anti-cytotoxic T-lymphocyte associated protein 4 (CTLA-4) as prior neoadjuvant/adjuvant treatment should not receive ipilimumab + nivolumab as investigator’s choice therapy”
> “Participants who have received an anti-PD-L1 agent as prior neoadjuvant/adjuvant treatment should not receive pembrolizumab as investigator’s choice therapy”

Source: [EU CTIS 2023-506686-66-01](https://euclinicaltrials.eu/ctis-public-api/retrieve/2023-506686-66-01)

<a id="topic-3.1.1.4-4"></a>

###### Tissue, measurable disease, and first-line status in the EU trial record

> “Has a representative archival metastatic tumor specimen in paraffin blocks with an associated pathology report or a minimum of 16 formalin-fixed paraffin embedded (FFPE) slides is mandatory.”
> “The participants in this study are frontline MUM patients. Participants are eligible for this trial if they are initially diagnosed with MUM or after therapy for localized UM that has subsequently metastasized.”
> “Has measurable disease per RECIST v1.1, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as ≥10 mm with computer tomography (CT) or magnetic resonance imaging (MRI) scan.”
> “Must be at least 18 years of age.”

Source: [EU CTIS 2023-506686-66-01](https://euclinicaltrials.eu/ctis-public-api/retrieve/2023-506686-66-01)

<a id="topic-3.1.1.4-5"></a>

###### Laboratory thresholds for adequate organ function in the EU trial record

> “Absolute neutrophil count (ANC) ≥ 1500/mm3 without the use of hematopoietic growth factors”
> “Hemoglobin ≥ 9.0 g/dL (must be at least 2 weeks post-red blood cell transfusion)”
> “AST and ALT ≤ 3 × ULN in the absence of documented liver metastases; ≤ 5 × ULN in the presence of liver metastases”
> “Serum albumin ≥ 3.0 g/dL.”
> “Creatinine clearance ≥ 45 mL/min by Cockcroft-Gault equation (see Appendix 1, Section 14.1).”

Source: [EU CTIS 2023-506686-66-01](https://euclinicaltrials.eu/ctis-public-api/retrieve/2023-506686-66-01)

<a id="topic-3.1.1.4-6"></a>

###### Syncope, cardiac, and concomitant medication exclusions in the EU trial record

> “History of syncope (except due to an acute medical condition [e.g., hemorrhage] within 6 months of the first dose of study treatment and is not likely to reoccur).”
> “Participants at high risk of falls should be considered ineligible.”
> “QTcF > 470 msec on baseline ECG (mean of baseline values).”
> “Has other clinically significant heart disease (e.g., uncontrolled arrhythmia or hypertension; history of labile hypertension or poor compliance with an antihypertensive regimen, symptomatic bradycardia)”
> “Has an allergy to mammalian meat products or gelatin.”

Source: [EU CTIS 2023-506686-66-01](https://euclinicaltrials.eu/ctis-public-api/retrieve/2023-506686-66-01)

<a id="topic-3.1.1.4-7"></a>

###### Contraindication to comparator options and restricted use of dacarbazine in the EU trial record

> “Contraindication for treatment with investigator’s choice alternatives (dacarbazine, ipilimumab + nivolumab, and pembrolizumab) as per applicable labelling.”
> “Participants may have a contraindication to one or two of the choices if he/she is a candidate for dosing with at least one investigator’s choice and meets all other study eligibility criteria.”
> “Choice of dacarbazine should only be made in the setting where treatment with immunotherapy is deemed likely to result in irreversible serious (or life threatening) AEs (e.g., severe active autoimmune disease requiring potent immunosuppression) and must be discussed with the Sponsor Medical Monitor.”

Source: [EU CTIS 2023-506686-66-01](https://euclinicaltrials.eu/ctis-public-api/retrieve/2023-506686-66-01)

<a id="heading-3.1.1.5"></a>

##### 3.1.1.5 Treatment

<a id="topic-3.1.1.5-1"></a>

###### Darovasertib and crizotinib doses, run-in, and comparator regimens in the ASCO 2026 presentation

| Arm or regimen | Dose shown in the study design figure |
| --- | --- |
| Phase 2a and phase 2b/3 selected-dose arm, darovasertib | “Darovasertib (300 mg BID)” |
| Phase 2a and phase 2b/3 combination arms, crizotinib | “Crizotinib (200 mg BID)” |
| Phase 2a lower-dose arm, darovasertib | “Darovasertib (200 mg BID)” |

Source: [Orloff et al. (2026a)](https://filecache.investorroom.com/mr5ir_ideayabio/616/OptimUM-02%20ASCO%20-%2026MAY2026.pdf)

> “Treatment will commence with a 7-day run-in of darovasertib monotherapy (at dose corresponding to the treatment arm, and the run-in may be extended if clinically indicated) prior to starting crizotinib.”
> “Treatment will continue until disease progression, death (any cause), unacceptable toxicity or treatment discontinuation”
> “Dacarbazine, dacarbazine (1000 mg/m2 Q3W). Ipi+Nivo, ipilimumab (3 mg/kg) + nivolumab (1 mg/kg) for 4 cycles followed by nivolumab (1mg/kg).”
> “Pembro, pembrolizumab (200 mg Q3W).”

Source: [Orloff et al. (2026a)](https://filecache.investorroom.com/mr5ir_ideayabio/616/OptimUM-02%20ASCO%20-%2026MAY2026.pdf)

<a id="topic-3.1.1.5-2"></a>

###### Route and schedule of each intervention in the ClinicalTrials.gov record

| Intervention | Quoted route and schedule |
| --- | --- |
| IDE196 (darovasertib) and crizotinib | “Dosed orally, twice daily” |
| Pembrolizumab | “IV administration every 3 weeks” |
| Ipilimumab | “IV administration every 3 weeks for 4 Cycles” |
| Nivolumab | “IV administration every 3 Weeks for 4 Cycles, thereafter every 4 Weeks maintenance” |
| Dacarbazine | “IV administration every 3 Weeks” |

Source: [ClinicalTrials.gov NCT05987332](https://clinicaltrials.gov/study/NCT05987332)

> “Participants will receive investigator's choice of Pembrolizumab, Ipilimumab + Nivolumab, or Dacarbazine.”

Source: [ClinicalTrials.gov NCT05987332](https://clinicaltrials.gov/study/NCT05987332)

<a id="topic-3.1.1.5-3"></a>

###### Comparator stratum in the investigator's choice arm (ASCO 2026 presentation)

| Investigator's choice treatment at baseline (stratification), n (%) | Investigator's choice arm (N=103) |
| --- | --- |
| Ipilimumab + nivolumab | “79 ( 76.7)” |
| Pembrolizumab or dacarbazine | “24 ( 23.3)” |

Source: [Orloff et al. (2026a)](https://filecache.investorroom.com/mr5ir_ideayabio/616/OptimUM-02%20ASCO%20-%2026MAY2026.pdf)

> “No patients received dacarbazine in the investigator’s choice arm”

Source: [Orloff et al. (2026a)](https://filecache.investorroom.com/mr5ir_ideayabio/616/OptimUM-02%20ASCO%20-%2026MAY2026.pdf)

<a id="topic-3.1.1.5-4"></a>

###### Comparator selection in the investigator's choice arm, ESMO 2026 poster

> “Ipilimumab-nivolumab was selected for 79 patients and pembrolizumab was selected for 24 patients for the control; none selected dacarbazine”

Source: [Piperno-Neumann et al. (2026c)](https://www.ideayabio.com/sites/default/files/publications/2026-11/ESMO-2026-Piperno-Neumann-OptimUM-02.pdf)

<a id="topic-3.1.1.5-5"></a>

###### Comparator received in the control arm as reported from the ASCO 2026 presentation

> “In the control arm, 76.7% of patients received ipilimumab/nivolumab, and the remainder received pembrolizumab. No patients ultimately received dacarbazine.”

Source: [Barbor (2026)](https://ascopost.com/articles/2026/08-august/darovasertib-plus-crizotinib-may-set-new-first-line-standard-in-hla-a2-negative-metastatic-uveal-melanoma/)

<a id="topic-3.1.1.5-6"></a>

###### Comparator composition in the topline release, which differs from the ASCO and ESMO counts

> “The ICT arm was composed of 76% (n=78) ipilimumab plus nivolumab (anti-CTLA-4/PD-1) and 24% (n=25) pembrolizumab (anti-PD-1).”

Source: [IDEAYA Biosciences press release, OptimUM-02 topline results (2026)](https://media.ideayabio.com/2026-04-13-IDEAYA-Biosciences-and-Servier-Announce-Positive-Topline-Results-from-Phase-2-3-Registrational-Trial-OptimUM-02-of-Darovasertib-in-Combination-with-Crizotinib-in-First-line-HLA-A-02-01-Negative-Metastatic-Uveal-Melanoma)

<a id="heading-3.1.1.6"></a>

##### 3.1.1.6 Study Outcomes

<a id="heading-3.1.1.6.1"></a>

###### 3.1.1.6.1 Rationale for Using Progression-free Survival by Blinded Independent Central Review as the Primary Endpoint

<a id="topic-3.1.1.6.1-1"></a>

###### Primary endpoints of each stage in the ClinicalTrials.gov record

| Primary outcome measure | Quoted description | Quoted time frame |
| --- | --- | --- |
| “Phase 2a: To determine the optimal dose of IDE196 + Crizotinib combination for Phase 2B and Phase 3 by evaluating the following:” | “dose exposure response (safety and efficacy) relationship, plasma concentration profiles and pharmacokinetic (PK) parameters, treatment-emergent Adverse Events (TEAEs), laboratory abnormalities, electrocardiogram (ECG), and vital sign changes and study treatment discontinuation due to AEs.” | “Approximately 5 months” |
| “Phase 2 Progression-Free Survival (PFS)” | “by blinded independent central review (BICR) of IDE196 + Crizotinib compared to investigator's choice of treatment per RECIST v1.1” | “Approximately 2 years” |
| “Phase 3 Overall Survival (OS) of IDE196 + Crizotinib compared to investigator's choice of treatment.” | “OS from randomization to date of death due to any cause” | “Approximately 4 years” |

Source: [ClinicalTrials.gov NCT05987332](https://clinicaltrials.gov/study/NCT05987332)

<a id="topic-3.1.1.6.1-2"></a>

###### Definitions of progression-free survival and overall survival in the EU trial record

> “PFS, defined as the time from randomization to the first documented date of disease progression or death due to any cause, whichever occurs first”
> “OS (time from randomization to date of death due to any cause”

Source: [EU CTIS 2023-506686-66-01](https://euclinicaltrials.eu/ctis-public-api/retrieve/2023-506686-66-01)

<a id="topic-3.1.1.6.1-3"></a>

###### Primary and other endpoints in the ASCO 2026 abstract

> “The primary endpoint for efficacy for phase 2 was progression-free survival (PFS) by RECIST (BICR).”
> “Other endpoints included investigator assessed PFS (PFSinv), objective response rate (ORR), duration of response (DOR), disease control rate (DCR: CR+ PR + SD ≥ 12 weeks), and safety.”
> “Overall survival, the phase 3 primary endpoint, will be presented as the data matures.”

Source: [Orloff et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO.2026.44.17_suppl.LBA9503)

<a id="topic-3.1.1.6.1-4"></a>

###### Median progression-free survival as the accelerated approval endpoint after the FDA Type C meeting, April 2023

> “Based on FDA meeting, initiating Phase 2/3 registrational trial in Q2 2023 in First-Line HLA-A2 negative MUM, with median PFS as primary endpoint for potential accelerated approval”
> “"These clinical data, considered with the FDA's guidance from our recent Type C meeting, provides IDEAYA with a registrational trial design in first-line HLA-A2 negative MUM patients which includes a path to potential accelerated approval based on median PFS as the primary endpoint," said Dr. Darrin Beaupre, M.D., Ph.D., Chief Medical Officer, IDEAYA Biosciences.”
> “The clinical trial design employs a Phase 2 portion with median PFS as a primary endpoint for potential accelerated approval.”
> “Efficacy data from the Phase 3 could support potential approval using median OS as a primary endpoint.”

Source: [IDEAYA Biosciences press release, FDA Type C meeting and interim phase 2 data (2023)](https://media.ideayabio.com/2023-04-23-IDEAYA-Announces-Positive-Interim-Phase-2-Data-for-Darovasertib-and-Crizotinib-Combination-and-Successful-FDA-Type-C-Meeting-on-Registrational-Trial-Design-for-Accelerated-Approval-in-First-Line-Metastatic-Uveal-Melanoma)

<a id="topic-3.1.1.6.1-5"></a>

###### Overall survival as the primary endpoint of the phase 3 confirmatory portion in the annual report for 2024

> “The protocol of the Phase 2/3 clinical trial design incorporates guidance and feedback following our Type C meeting with the FDA in March 2023.”
> “Patients enrolled in Phase 2 will continue on treatment within the same study and will be considered, together with additional enrolled patients, to evaluate OS as the primary endpoint of the Phase 3 confirmatory portion of the clinical trial to support a potential full approval.”

Source: [IDEAYA Biosciences Form 10-K (2025)](https://www.sec.gov/Archives/edgar/data/1676725/000095017025022183/idya-20241231.htm)

<a id="topic-3.1.1.6.1-6"></a>

###### Accelerated approval on a surrogate endpoint as described in the annual report for 2025

> “Accelerated approval is intended to allow for earlier approval of drugs that treat serious conditions and fill an unmet medical need based on a demonstration of effectiveness on a surrogate endpoint, with the requirement to conduct one or more additional studies to confirm the anticipated clinical benefit to obtain full traditional approval.”

Source: [IDEAYA Biosciences Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1676725/000119312526054533/idya-20251231.htm)

<a id="topic-3.1.1.6.1-7"></a>

###### Regulatory role of each primary endpoint in the full enrollment release, December 2025

> “The primary endpoints are median PFS and median OS, which will be used to support a potential accelerated approval and full approval in the United States, respectively.”

Source: [IDEAYA Biosciences press release, OptimUM-02 full enrollment (2025)](https://media.ideayabio.com/2025-12-11-IDEAYA-Biosciences-Completes-Targeted-Full-Enrollment-in-Randomized-Pivotal-Phase-2-3-Trial-OptimUM-02-of-Darovasertib-in-Combination-with-Crizotinib-in-First-line-HLA-A2-Negative-Metastatic-Uveal-Melanoma)

<a id="topic-3.1.1.6.1-8"></a>

###### Regulatory role of each primary endpoint in the topline and ASCO 2026 releases

> “The primary endpoint is median PFS as assessed by BICR, which will be used to support an initial NDA submission in the United States.”

Source: [IDEAYA Biosciences press release, OptimUM-02 topline results (2026)](https://media.ideayabio.com/2026-04-13-IDEAYA-Biosciences-and-Servier-Announce-Positive-Topline-Results-from-Phase-2-3-Registrational-Trial-OptimUM-02-of-Darovasertib-in-Combination-with-Crizotinib-in-First-line-HLA-A-02-01-Negative-Metastatic-Uveal-Melanoma)

> “The primary endpoint to support accelerated approval is median progression-free survival (PFS) as assessed by blinded independent central review (BICR).”

Source: [IDEAYA Biosciences press release, OptimUM-02 ASCO 2026 data (2026)](https://media.ideayabio.com/2026-06-01-IDEAYA-Biosciences-and-Servier-Provide-Complete-Data-from-Phase-2-3-Registrational-OptimUM-02-Trial-of-the-Darovasertib-Combination-in-First-Line-HLA-A2-01-Negative-Metastatic-Uveal-Melanoma-in-a-Late-Breaking-Oral-Presentation-at-ASCO)

<a id="topic-3.1.1.6.1-9"></a>

###### FDA guidance on progression-free survival as a regulatory endpoint

> “PFS is defined as the time from randomization until objective tumor progression or death, whichever occurs first.”
> “Compared with TTP, PFS is the preferred regulatory endpoint.”
> “PFS can reflect tumor growth and be assessed before the determination of a survival benefit. Its determination is not confounded by subsequent therapy. For a given sample size, the magnitude of effect on PFS can be larger than the effect on overall survival. Data are usually insufficient to allow a robust evaluation of the correlation between effects on overall survival and PFS.”
> “Treatment effect measured by PFS can be a surrogate endpoint to support accelerated approval, a surrogate endpoint to support traditional approval, or it can represent direct clinical benefit based on the specific disease, context of use, magnitude of the effect, the disease setting, location of metastatic sites, available therapy, the risk-benefit relationship, and the clinical consequences of delaying or preventing progression in key disease sites (e.g., delay of new lesions in the brain or spine) or delaying administration of more toxic therapies.”

Source: [FDA guidance, Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics (2018)](https://www.fda.gov/media/71195/download)

<a id="topic-3.1.1.6.1-10"></a>

###### FDA guidance on blinded central review of tumor-based endpoints

> “When the primary study endpoint is based on tumor measurements (e.g., PFS or ORR), tumor assessments generally should be verified by central reviewers blinded to study treatments (see Appendix) to ascertain lack of assessment bias.”
> “An independent endpoint review committee (IRC) can minimize bias in radiographic interpretation of the radiological findings and independent adjudication of assessments.”

Source: [FDA guidance, Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics (2018)](https://www.fda.gov/media/71195/download)

<a id="topic-3.1.1.6.1-11"></a>

###### FDA guidance on overall survival as an endpoint

> “Overall survival is defined as the time from randomization until death from any cause and is measured in the intent-to-treat population. Survival is considered the most reliable cancer endpoint, and when studies can be conducted to adequately assess survival, it is usually the preferred endpoint.”
> “Overall survival should be evaluated in randomized controlled studies.”

Source: [FDA guidance, Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics (2018)](https://www.fda.gov/media/71195/download)

<a id="topic-3.1.1.6.1-12"></a>

###### FDA draft guidance on a single randomized trial supporting accelerated approval and verifying benefit

> “Alternatively, sponsors could design a single randomized controlled trial to support accelerated approval, that is also powered for the longer-term clinical endpoint with follow-up in the same trial to verify clinical benefit (i.e., “one-trial” approach).”

Source: [FDA draft guidance on accelerated approval of oncology therapeutics (2023)](https://www.fda.gov/media/166431/download)

> “Although single-arm trials have been commonly used to support accelerated approval, a randomized controlled trial is the preferred approach as it provides a more robust efficacy and safety assessment and allows for direct comparisons to an available therapy.”

Source: [FDA guidance page, accelerated approval of oncology therapeutics (2023)](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-trial-considerations-support-accelerated-approval-oncology-therapeutics)

<a id="topic-3.1.1.6.1-13"></a>

###### Historical progression-free and overall survival in metastatic uveal melanoma cited in the ESMO 2026 poster

> “Historically, mUM has been associated with a median progression free survival (mPFS) of 2.8 months and a median overall survival (mOS) of ~12 months”

Source: [Piperno-Neumann et al. (2026c)](https://www.ideayabio.com/sites/default/files/publications/2026-11/ESMO-2026-Piperno-Neumann-OptimUM-02.pdf)

<a id="topic-3.1.1.6.1-14"></a>

###### Disease control definition and imaging interval as reported from the ASCO 2026 presentation

> “Dr. Orloff noted that disease control was defined as complete response, partial response, or stable disease lasting at least 12 weeks, with imaging performed every 6 weeks.”

Source: [Barbor (2026)](https://ascopost.com/articles/2026/08-august/darovasertib-plus-crizotinib-may-set-new-first-line-standard-in-hla-a2-negative-metastatic-uveal-melanoma/)

<a id="topic-3.1.1.6.1-15"></a>

###### Secondary efficacy and safety endpoints in the ClinicalTrials.gov record

> “Treatment emergent adverse events will be summarized by all AEs, including by Grade ≥3, all treatment related AEs, all AEs leading to study drug modifications or discontinuations, all SAEs as measured by CTCAE v5.0.”
> “Phase 2b + 3: Progression-Free Survival (PFS) per Investigator Assessment of IDE196 + Crizotinib compared to investigator's choice of treatment .”
> “Objective Response Rate (ORR) per BICR and Investigator assessment of IDE196 + Crizotinib compared to investigator's choice of treatment”
> “Duration of Response (DOR) per BICR and Investigator assessment of IDE196 + Crizotinib compared to investigator's choice of treatment”
> “Disease Control Rate (DCR) per BICR and Investigator Assessment of IDE196 + Crizotinib compared to investigator's choice of treatment.”
> “Time to response as assessed by Investigator and BICR”

Source: [ClinicalTrials.gov NCT05987332](https://clinicaltrials.gov/study/NCT05987332)

<a id="topic-3.1.1.6.1-16"></a>

###### Definitions of response endpoints in the EU trial record

> “ORR, defined as the proportion of participants with a complete response (CR) or a partial response (PR) as best objective response (BOR)”
> “Disease control rate (DCR), defined as CR or PR, or stable disease (SD) ≥ 12 weeks”
> “DOR, defined as the time from the first documented evidence of a CR or PR until disease progression or death due to the underlying disease, whichever occurs first”

Source: [EU CTIS 2023-506686-66-01](https://euclinicaltrials.eu/ctis-public-api/retrieve/2023-506686-66-01)

<a id="topic-3.1.1.6.1-17"></a>

###### Patient-reported outcome endpoints in the ClinicalTrials.gov record and the EU trial record

> “Change from baseline over time and between treatment arms in Global health status and quality of life will be assessed using the EORTC QLQ-C30 questionnaire.”
> “The score range for the EORTC QLQ-C30 is from 0 to 100, with higher scores indicating better functioning and better global health status and health-related in EORTC QLQ-C30 scores”

Source: [ClinicalTrials.gov NCT05987332](https://clinicaltrials.gov/study/NCT05987332)

> “Change from baseline over time and between treatment arms in European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 and EuroQoL (EQ)-5D- 5L scores”

Source: [EU CTIS 2023-506686-66-01](https://euclinicaltrials.eu/ctis-public-api/retrieve/2023-506686-66-01)

<a id="heading-3.1.1.7"></a>

##### 3.1.1.7 Statistical Analysis Description

<a id="heading-3.1.1.7.1"></a>

###### 3.1.1.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.1.7.1-1"></a>

###### Planned enrollment of 420 participants in the current ClinicalTrials.gov record

| Field | Quoted record |
| --- | --- |
| Enrollment (estimated) | “420” |

Source: [ClinicalTrials.gov NCT05987332](https://clinicaltrials.gov/study/NCT05987332)

<a id="topic-3.1.1.7.1-2"></a>

###### Planned enrollment of 420 participants from record version 39, November 2024

| Field | Quoted record |
| --- | --- |
| Record version viewed | “Viewing V39 (2024-11-05)” |
| Enrollment | “420 [Estimated]” |

Source: [ClinicalTrials.gov NCT05987332 version 39](https://clinicaltrials.gov/study/NCT05987332?tab=history&a=39)

<a id="topic-3.1.1.7.1-3"></a>

###### Planned enrollment of 380 participants in record version 1, August 2023, superseded in November 2024

| Field | Quoted record |
| --- | --- |
| Record version viewed | “Viewing V1 (2023-08-03)” |
| Enrollment | “380 [Estimated]” |

Source: [ClinicalTrials.gov NCT05987332 version 1](https://clinicaltrials.gov/study/NCT05987332?tab=history&a=1)

<a id="topic-3.1.1.7.1-4"></a>

###### Planned phase 2 and phase 3 sample sizes after the FDA Type C meeting, April 2023, superseded in December 2025

> “In the Phase 2 portion of the clinical trial, approximately 230 patients will be randomized on a 2:1 basis for treatment with the darovasertib and crizotinib combination in the treatment arm or investigators choice in the control arm, selected from a combination of ipilimumab (ipi) and nivolumab (nivo), PD1-targeted monotherapy or DTIC.”
> “The Phase 2 portion of the clinical trial contemplates an efficacy and safety data set of approximately 200 patients randomized 2:1 with the treatment arm at the move forward dose to support a potential accelerated approval based on median PFS by blinded independent central review (BICR) as a primary endpoint.”
> “Patients enrolled in Phase 2 at the selected dose would continue on treatment and be included in the Phase 3 study analysis, supplemented by enrollment of approximately 120 additional patients into the Phase 3 portion of the clinical trial with 2:1 randomization on the same basis as the Phase 2 portion.”

Source: [IDEAYA Biosciences press release, FDA Type C meeting and interim phase 2 data (2023)](https://media.ideayabio.com/2023-04-23-IDEAYA-Announces-Positive-Interim-Phase-2-Data-for-Darovasertib-and-Crizotinib-Combination-and-Successful-FDA-Type-C-Meeting-on-Registrational-Trial-Design-for-Accelerated-Approval-in-First-Line-Metastatic-Uveal-Melanoma)

<a id="topic-3.1.1.7.1-5"></a>

###### Completed enrollment of 435 participants in the full enrollment release, December 2025

> “SOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leading precision medicine oncology company, today announced it has completed its targeted full enrollment of 435 patients in the registration-enabling Phase 2/3 trial (OptimUM-02) evaluating darovasertib, the company's investigational oral protein kinase C (PKC) inhibitor, in combination with Pfizer's crizotinib, an oral c-MET inhibitor, in first line (1L) HLA*A2-negative metastatic uveal melanoma (mUM).”

Source: [IDEAYA Biosciences press release, OptimUM-02 full enrollment (2025)](https://media.ideayabio.com/2025-12-11-IDEAYA-Biosciences-Completes-Targeted-Full-Enrollment-in-Randomized-Pivotal-Phase-2-3-Trial-OptimUM-02-of-Darovasertib-in-Combination-with-Crizotinib-in-First-line-HLA-A2-Negative-Metastatic-Uveal-Melanoma)

<a id="topic-3.1.1.7.1-6"></a>

###### Completed enrollment of 437 participants in the annual report for 2025

> “In December 2025, we completed full enrollment of 437 patients in OptimUM-02, and plan to submit overall survival (OS) data from these patients, when available, to support a full approval filing in this indication.”

Source: [IDEAYA Biosciences Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1676725/000119312526054533/idya-20251231.htm)

<a id="topic-3.1.1.7.1-7"></a>

###### Statistical design of the phase 2b primary analysis in the ASCO 2026 presentation

> “130 PFS events were required to detect a hazard ratio of 0.55 with 90% power”
> “Stratified log-rank test at a 1-sided α of 2.5%”
> “The median PFS in the control arm was assumed to be 3 months”
> “The target HR of 0.55 represents a 45% reduction in the risk of disease progression or death”
> “Translates to approximately 5.5 months median PFS in the darovasertib + crizotinib arm assuming exponential distributions”

Source: [Orloff et al. (2026a)](https://filecache.investorroom.com/mr5ir_ideayabio/616/OptimUM-02%20ASCO%20-%2026MAY2026.pdf)

<a id="topic-3.1.1.7.1-8"></a>

###### Participants analyzed in the ASCO 2026 release

> “OptimUM-02 is a global, registrational Phase 2/3 trial evaluating a total of 313 patients with 1L HLA*A2:01 negative mUM, randomized 2:1 to the darovasertib combination or an investigator's choice of therapy (ICT) arm reflective of real-world clinical practice that included ipilimumab plus nivolumab (anti-CTLA-4/PD-1) or pembrolizumab (anti-PD-1).”

Source: [IDEAYA Biosciences press release, OptimUM-02 ASCO 2026 data (2026)](https://media.ideayabio.com/2026-06-01-IDEAYA-Biosciences-and-Servier-Provide-Complete-Data-from-Phase-2-3-Registrational-OptimUM-02-Trial-of-the-Darovasertib-Combination-in-First-Line-HLA-A2-01-Negative-Metastatic-Uveal-Melanoma-in-a-Late-Breaking-Oral-Presentation-at-ASCO)

<a id="topic-3.1.1.7.1-9"></a>

###### Testing hierarchy and alpha allocation for secondary endpoints and overall survival

No evidence found.

<a id="heading-3.1.1.7.2"></a>

###### 3.1.1.7.2 Description of Analysis Sets

<a id="topic-3.1.1.7.2-1"></a>

###### Intent-to-treat efficacy population of the phase 2b portion in the ASCO 2026 presentation

> “All patients in the ITT population setting (phase 2b portion of trial)”
> “Darovasertib 300 mg + crizotinib 200 mg (n=210)”
> “Investigator’s Choice (control, n=103)”
> “Analysis based on both BICR and Investigator assessments”

Source: [Orloff et al. (2026a)](https://filecache.investorroom.com/mr5ir_ideayabio/616/OptimUM-02%20ASCO%20-%2026MAY2026.pdf)

<a id="topic-3.1.1.7.2-2"></a>

###### Safety population of 338 and efficacy population of 313 in the ASCO 2026 abstract

> “Overall 338 patients received at least one dose of study treatment (safety population), 313 comprised the efficacy population.”

Source: [Orloff et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO.2026.44.17_suppl.LBA9503)

<a id="topic-3.1.1.7.2-3"></a>

###### Stratified and unstratified subgroup models in the ESMO 2026 poster

> “Unstratified: Subgroup hazard ratios were estimated from a single Cox proportional hazards model including treatment, subgroup, and treatment-by-subgroup interaction terms, with a common baseline hazard across subgroup levels.”
> “Stratified: The treatment hazard ratio was estimated using a Cox proportional hazards model stratified by prespecified factors, allowing each stratum to have its own baseline hazard while estimating a common treatment effect across strata.”
> “Efficacy, including progression-free survival (PFS) and objective response rate (ORR), were evaluated by BICR across key subgroups”

Source: [Piperno-Neumann et al. (2026c)](https://www.ideayabio.com/sites/default/files/publications/2026-11/ESMO-2026-Piperno-Neumann-OptimUM-02.pdf)

<a id="heading-3.1.1.8"></a>

##### 3.1.1.8 Results

<a id="heading-3.1.1.8.1"></a>

###### 3.1.1.8.1 Participant Disposition

<a id="topic-3.1.1.8.1-1"></a>

###### Participants without a post-baseline response assessment, by arm (ASCO 2026 presentation)

| Best overall response category | Darovasertib plus crizotinib (N=210), n (%) | Investigator's choice (N=103), n (%) |
| --- | --- | --- |
| Not reported (no post-baseline assessment), by BICR and by investigator | “12 (5.7)” | “24 (23.3)” |

Source: [Orloff et al. (2026a)](https://filecache.investorroom.com/mr5ir_ideayabio/616/OptimUM-02%20ASCO%20-%2026MAY2026.pdf)

> “Refers to the patients who did not have any post-baseline assessments. Investigator Choice Treatment: (24): withdrew consent before treatment (17), before 1st post-baseline scan (2); due to AE (1, G3 hypoxia), clinical progression (1) and death (2), scan not recoverable from outside facility (1).”
> “Darovasertib + crizotinib Treatment: (12); due to death (7), withdrew consent before 1st post-baseline scan (1); due to clinical progression (1), scans performed after clinical cutoff (1), scans not performed at EOT or during post-treatment period (2).”

Source: [Orloff et al. (2026a)](https://filecache.investorroom.com/mr5ir_ideayabio/616/OptimUM-02%20ASCO%20-%2026MAY2026.pdf)

<a id="topic-3.1.1.8.1-2"></a>

###### Median follow-up and median duration of treatment in the ASCO 2026 presentation

> “Median follow-up for the population was 7.4 months.”
> “Median duration of treatment for darovasertib and crizotinib was 6.31 months; for pembrolizumab, ipilimumab, and nivolumab, the median duration of treatment were 2.87, 2.56, and 2.79 months, respectively.”

Source: [Orloff et al. (2026a)](https://filecache.investorroom.com/mr5ir_ideayabio/616/OptimUM-02%20ASCO%20-%2026MAY2026.pdf)

<a id="topic-3.1.1.8.1-3"></a>

###### Discontinuation of study treatment for adverse events, ASCO 2026 abstract

> “AEs led to discontinuation & dose reduction of darova in 3.8% & 23.8% and crizo in 10.9% & 27.2% subjects. In the IC arm, 19.2% discontinued due to AEs.”

Source: [Orloff et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO.2026.44.17_suppl.LBA9503)

<a id="heading-3.1.1.8.2"></a>

###### 3.1.1.8.2 Baseline Characteristics

<a id="topic-3.1.1.8.2-1"></a>

###### Demographics, performance status, and LDH stratum (ASCO 2026 presentation)

| Characteristic | Darovasertib plus crizotinib (N=210) | Investigator's choice (N=103) |
| --- | --- | --- |
| Age, mean (range), years | “61.1 (22 - 85)” | “61.5 (29 - 85)” |
| Female, n (%) | “101 (48.1)” | “52 (50.5)” |
| Race, White, n (%) | “177 (84.3)” | “83 (80.6)” |
| Race, non-White, n (%) | “4 (1.9)” | “4 (3.9)” |
| Race, not reported, n (%) | “29 ( 13.8)” | “16 ( 15.5)” |
| ECOG 0, n (%) | “162 (77.1)” | “87 (84.5)” |
| ECOG 1, n (%) | “48 (22.9)” | “16 (15.5)” |
| Stratification LDH at baseline (IRT), ≤ ULN, n (%) | “120 (57.1)” | “62 (60.2)” |
| Stratification LDH at baseline (IRT), > ULN to < 2x ULN, n (%) | “65 (31.0)” | “29 (28.2)” |
| Stratification LDH at baseline (IRT), ≥ 2x ULN, n (%) | “25 (11.9)” | “12 (11.7)” |

Source: [Orloff et al. (2026a)](https://filecache.investorroom.com/mr5ir_ideayabio/616/OptimUM-02%20ASCO%20-%2026MAY2026.pdf)

<a id="topic-3.1.1.8.2-2"></a>

###### Baseline tumor characteristics and metastatic sites (ASCO 2026 presentation)

| Characteristic | Darovasertib plus crizotinib (N=210) | Investigator's choice (N=103) |
| --- | --- | --- |
| Time since first metastatic diagnosis, median (range), years | “0.18 (0.0 – 8.1)” | “0.19 (0.0 – 4.6)” |
| Size of largest metastatic lesion ≤ 3 cm, n (%) | “119 ( 56.7)” | “67 ( 65.0)” |
| Size of largest metastatic lesion 3.1 to 8.0 cm, n (%) | “73 ( 34.8)” | “31 ( 30.1)” |
| Size of largest metastatic lesion ≥ 8.1 cm, n (%) | “18 (  8.6)” | “5 (  4.9)” |
| Hepatic disease only, n (%) | “127 ( 60.5)” | “65 ( 63.1)” |
| Extrahepatic disease only, n (%) | “11 (  5.2)” | “7 (  6.8)” |
| Hepatic and extrahepatic disease, n (%) | “72 ( 34.3)” | “31 ( 30.1)” |

Source: [Orloff et al. (2026a)](https://filecache.investorroom.com/mr5ir_ideayabio/616/OptimUM-02%20ASCO%20-%2026MAY2026.pdf)

<a id="topic-3.1.1.8.2-3"></a>

###### Participants by age group and geographic region in the PFS subgroup figure (ASCO 2026 presentation)

| Subgroup | Participants, darovasertib plus crizotinib and control |
| --- | --- |
| Age under 65 years | “118, 64” |
| Age 65 years or older | “92, 39” |
| Geographic region, USA | “74, 36” |
| Geographic region, non-USA | “136, 67” |

Source: [Orloff et al. (2026a)](https://filecache.investorroom.com/mr5ir_ideayabio/616/OptimUM-02%20ASCO%20-%2026MAY2026.pdf)

<a id="topic-3.1.1.8.2-4"></a>

###### Comparator stratum and prior oligometastatic surgery (ESMO 2026 poster)

| Characteristic | Darovasertib 300 mg plus crizotinib 200 mg (N=210) | Investigator's choice (N=103) |
| --- | --- | --- |
| Control at baseline, ipilimumab + nivolumab, n (%) | “158 (75.2)” | “79 ( 76.7)” |
| Control at baseline, pembrolizumab or dacarbazine, n (%) | “52 (24.8)” | “24 ( 23.3)” |
| Prior oligometastatic-directed surgery, n (%) | “5 (2.4)” | “6 (5.8)” |

Source: [Piperno-Neumann et al. (2026c)](https://www.ideayabio.com/sites/default/files/publications/2026-11/ESMO-2026-Piperno-Neumann-OptimUM-02.pdf)

> “Baseline characteristics were generally similar across both arms”
> “Key relevant prognostic factors included ECOG performance status, site of metastasis, tumor burden, and baseline LDH levels”
> “There were more ECOG 1 and bulky liver lesions in the darova+criz group”

Source: [Piperno-Neumann et al. (2026c)](https://www.ideayabio.com/sites/default/files/publications/2026-11/ESMO-2026-Piperno-Neumann-OptimUM-02.pdf)

<a id="topic-3.1.1.8.2-5"></a>

###### Balance of baseline characteristics as reported from the ASCO 2026 presentation

> “Baseline characteristics were generally balanced between the two arms, although Dr. Orloff noted that numerically more patients in the darovasertib/crizotinib arm had an ECOG PS of 1 and larger tumors. Baseline LDH and metastatic patterns were well balanced; most patients had liver involvement.”

Source: [Barbor (2026)](https://ascopost.com/articles/2026/08-august/darovasertib-plus-crizotinib-may-set-new-first-line-standard-in-hla-a2-negative-metastatic-uveal-melanoma/)

<a id="heading-3.1.1.8.3"></a>

###### 3.1.1.8.3 Efficacy Results

<a id="topic-3.1.1.8.3-1"></a>

###### Progression-free survival, 313 participants of the phase 2b/3 portion, data cutoff January 23, 2026

> “Topline results were from a total of 313 patients enrolled in the Phase 2b/3 portion of the trial as of the cut-off date of January 23, 2026. The PFS analysis was based on a total of 159 events.”
> “Patients treated with the darovasertib combination reduced their risk of disease progression as assessed by BICR by 58% (Hazard Ratio of 0.42; 95% CI: 0.30, 0.59; p-value: <0.0001) and achieved a statistically significant improvement in median PFS of 6.9 months versus 3.1 months in the ICT arm.”

Source: [IDEAYA Biosciences press release, OptimUM-02 topline results (2026)](https://media.ideayabio.com/2026-04-13-IDEAYA-Biosciences-and-Servier-Announce-Positive-Topline-Results-from-Phase-2-3-Registrational-Trial-OptimUM-02-of-Darovasertib-in-Combination-with-Crizotinib-in-First-line-HLA-A-02-01-Negative-Metastatic-Uveal-Melanoma)

> “The median PFS by BICR was 6.9 months for darova+crizo (5.6, 8.3) and 3.1 months for IC (1.8, 4.2); HR: 0.42, p<.0001. Median PFSinv was 6.7 months (5.6, 8.2) and 2.7 months (1.7, 4.1) resp; HR 0.36, p< 0.0001.”

Source: [Orloff et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO.2026.44.17_suppl.LBA9503)

| Outcome | By blinded independent central review | By investigator assessment |
| --- | --- | --- |
| Median PFS, darovasertib plus crizotinib, months (95% CI) | “Darova + Criz: 6.9 (5.6, 8.3)” | “Darova + Criz: 6.7 (5.6, 8.2)” |
| Median PFS, control, months (95% CI) | “Control: 3.1 (1.8, 4.2)” | “Control: 2.7 (1.7, 4.1)” |
| Hazard ratio (95% CI) | “HR = 0.42 (0.30, 0.59)” | “HR = 0.36 (0.26, 0.50)” |

Source: [Orloff et al. (2026a)](https://filecache.investorroom.com/mr5ir_ideayabio/616/OptimUM-02%20ASCO%20-%2026MAY2026.pdf)

> “58% by BICR (HR: 0.42); 64% by investigator assessment (HR: 0.36), p < 0.0001”

Source: [Orloff et al. (2026a)](https://filecache.investorroom.com/mr5ir_ideayabio/616/OptimUM-02%20ASCO%20-%2026MAY2026.pdf)

<a id="topic-3.1.1.8.3-2"></a>

###### Objective response, best overall response, duration of response, and disease control, 210 and 103 participants by arm

> “Patients treated with the darovasertib combination had an ORR of 37.1% (78/210) and 39.5% (83/210) as assessed by BICR and investigator, respectively, compared to 5.8% (6/103) and 1.9% (2/103) in the ICT arm (p-value: <0.0001).”
> “The darovasertib combination led to a disease control rate of 73.3% (154/210) and 74.3% (156/210) by BICR and investigator assessment, respectively, compared to 31.1% (32/103) and 27.2% (28/103) in the ICT control arm.”
> “The median duration of response was 6.8 months (95% CI: 5.5, 11.3) by BICR and 6.8 months (95% CI: 4.8, 9.7) by investigator assessment based on a median follow-up time of 7.4 months as of the cutoff date.”

Source: [IDEAYA Biosciences press release, OptimUM-02 ASCO 2026 data (2026)](https://media.ideayabio.com/2026-06-01-IDEAYA-Biosciences-and-Servier-Provide-Complete-Data-from-Phase-2-3-Registrational-OptimUM-02-Trial-of-the-Darovasertib-Combination-in-First-Line-HLA-A2-01-Negative-Metastatic-Uveal-Melanoma-in-a-Late-Breaking-Oral-Presentation-at-ASCO)

| Outcome | BICR, darovasertib plus crizotinib (N=210) | BICR, investigator's choice (N=103) | Investigator, darovasertib plus crizotinib (N=210) | Investigator, investigator's choice (N=103) |
| --- | --- | --- | --- | --- |
| Complete or partial response, n (%) | “78 (37.1)” | “6 (5.8)” | “83 (39.5)” | “2 (1.9)” |
| Objective response rate, 95% CI | “30.6, 44.1” | “2.2, 12.3” | “32.9, 46.5” | “0.2, 6.8” |
| Objective response, odds ratio (95% CI) | “10.8 (4.4, 26.4)” | Reference | “34.6 (8.1, 146.9)” | Reference |
| Median duration of response, months (95% CI) | “6.8 (5.5, 11.3)” | “NE” | “6.8 (4.8, 9.7)” | “NE” |
| Complete response, partial response, or stable disease for at least 12 weeks, n (%) | “154 (73.3)” | “32 (31.1)” | “156 (74.3)” | “28 (27.2)” |
| Disease control rate, 95% CI | “66.8, 79.2” | “22.3, 40.9” | “67.8, 80.1” | “18.9, 36.8” |
| Disease control, odds ratio (95% CI) | “7.7 (4.3, 13.5)” | Reference | “9.5 (5.3, 17.0)” | Reference |

Source: [Orloff et al. (2026a)](https://filecache.investorroom.com/mr5ir_ideayabio/616/OptimUM-02%20ASCO%20-%2026MAY2026.pdf)

| Best overall response, n (%) | BICR, darovasertib plus crizotinib (N=210) | BICR, investigator's choice (N=103) | Investigator, darovasertib plus crizotinib (N=210) | Investigator, investigator's choice (N=103) |
| --- | --- | --- | --- | --- |
| Complete response | “5 (2.4)” | “0” | “0” | “0” |
| Partial response | “73 (34.8)” | “6 (5.8)” | “83 (39.5)” | “2 (1.9)” |
| Stable disease | “107 (51.0)” | “43 (41.7)” | “99 (47.1)” | “39 (37.9)” |
| Progressive disease | “13 (6.2)” | “29 (28.2)” | “15 (7.1)” | “34 (33.0)” |
| Non-evaluable by RECIST | “0” | “1 (1.0)” | “1 (0.5)” | “4 (3.9)” |

Source: [Orloff et al. (2026a)](https://filecache.investorroom.com/mr5ir_ideayabio/616/OptimUM-02%20ASCO%20-%2026MAY2026.pdf)

<a id="topic-3.1.1.8.3-3"></a>

###### Response, disease control, and duration of response, ASCO 2026 abstract

> “BICR ORR {37.1% [CR 2.4%; PR 34.8%] vs. 5.8% [CR 0%, PR 5.8%], DCR (73.3% vs 31.1%), DOR (median 6.8 months vs. Non-Evaluable) as well as ORRinv [39.5% vs. 1.9%], DCRinv [74.3% vs. 27.2%] and DORinv (6.8 months vs. NE) all favored darova+crizo (p-value < 0.0001).”

Source: [Orloff et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO.2026.44.17_suppl.LBA9503)

<a id="topic-3.1.1.8.3-4"></a>

###### Tumor shrinkage on waterfall plots and subgroup consistency as reported from the ASCO 2026 presentation

> “Dr. Orloff also noted that the waterfall plots showed tumor reduction in nearly 90% of patients in the darovasertib/crizotinib arm compared with about 35% in the control arm.”
> “The progression-free survival benefit was observed across the analyzed subgroups, including baseline LDH, investigator’s choice treatment category, age, sex, ECOG performance status, geographic region, largest target lesion size, and metastatic site.”

Source: [Barbor (2026)](https://ascopost.com/articles/2026/08-august/darovasertib-plus-crizotinib-may-set-new-first-line-standard-in-hla-a2-negative-metastatic-uveal-melanoma/)

<a id="topic-3.1.1.8.3-5"></a>

###### Objective response and median progression-free survival by BICR in subgroups, efficacy population of 313 participants (ESMO 2026 poster, stratified analysis)

| Subgroup (n, darovasertib plus crizotinib and control) | ORR by BICR, darovasertib plus crizotinib (%) | ORR by BICR, control (%) | Median PFS by BICR, darovasertib plus crizotinib (months) | Median PFS by BICR, control (months) |
| --- | --- | --- | --- | --- |
| LDH normal (n=120, 62) | “46.7” | “8.1” | “8.4” | “4.2” |
| LDH above ULN and below 2x ULN (n=65, 29) | “27.7” | “3.4” | “5.7” | “1.8” |
| LDH 2x ULN or higher (n=25, 12) | “16.0” | “0” | “3.1” | “1.7” |
| Hepatic metastases (n=127, 65) | “45.7” | “3.1” | “8.3” | “2.9” |
| Extrahepatic metastases only (n=11, 7) | “27.3” | “0” | “6.7” | “8.3” |
| Hepatic and extrahepatic metastases (n=72, 31) | “23.6” | “12.9” | “4.9” | “2.8” |
| ECOG PS 0 (n=162, 87) | “38.3” | “5.8” | “6.8” | “3.1” |
| ECOG PS 1 (n=48, 16) | “33.3” | “6.3” | “6.9” | “3.1” |
| Largest lesion below 3 cm (n=119, 67) | “42.9” | “6.0” | “8.3” | “4.0” |
| Largest lesion 3 to 8 cm (n=73, 31) | “34.3” | “6.5” | “5.6” | “1.6” |
| Largest lesion 8 cm or larger (n=18, 5) | “11.1” | “0” | “4.2” | “1.7” |
| Control stratum ipilimumab plus nivolumab (n=158, 79) | “37.3” | “5.1” | “6.9” | “3.1” |
| Control stratum pembrolizumab or dacarbazine (n=52, 24) | “36.5” | “8.3” | “5.8” | “2.8” |

Source: [Piperno-Neumann et al. (2026c)](https://www.ideayabio.com/sites/default/files/publications/2026-11/ESMO-2026-Piperno-Neumann-OptimUM-02.pdf)

> “Overall, 313 patients (darova+criz: 210; control:103) were enrolled and included in the analyses (Table 1)”
> “The median PFS by BICR was 6.9 months for darova+criz (5.6, 8.3) and 3.1 months for IC (1.8, 4.2); HR: 0.42, p<0.0001 (Table 2)”
> “Results were generally consistent for stratified and unstratified analyses”
> “PFS results were generally consistent across key subgroups, with most favoring darova+criz over control (Figure 2)”
> “Tumor response, as assessed by ORR, generally favored darova+criz across subgroups (Figure 3)”
> “BICR results for PFS and ORR were generally consistent regardless of baseline LDH, location of metastases, ECOG PS, lesion size, or investigator’s choice of therapy”

Source: [Piperno-Neumann et al. (2026c)](https://www.ideayabio.com/sites/default/files/publications/2026-11/ESMO-2026-Piperno-Neumann-OptimUM-02.pdf)

<a id="topic-3.1.1.8.3-6"></a>

###### Subgroup findings in the ASCO 2026 and ESMO 2026 releases

> “Treatment with the darovasertib combination demonstrated a consistent and meaningful improvement in median PFS relative to the ICT arm across a broad range of patient subgroups, including age and gender, type of immune therapy used in ICT, LDH stratification, ECOG status and site of metastasis.”

Source: [IDEAYA Biosciences press release, OptimUM-02 ASCO 2026 data (2026)](https://media.ideayabio.com/2026-06-01-IDEAYA-Biosciences-and-Servier-Provide-Complete-Data-from-Phase-2-3-Registrational-OptimUM-02-Trial-of-the-Darovasertib-Combination-in-First-Line-HLA-A2-01-Negative-Metastatic-Uveal-Melanoma-in-a-Late-Breaking-Oral-Presentation-at-ASCO)

> “The ESMO data builds on these results, showing consistent improvements in ORR and PFS compared to ICT across multiple clinically relevant subgroups, including baseline lactate dehydrogenase (LDH) levels, ECOG performance status, largest target lesion size and choice of ICT used in the control arm.”
> “As expected, patients with higher tumor burden (lesion size ≥ 8 cm, LDH ≥ 2X ULN) had a worse prognosis, however outcomes were still better with the darovasertib combination compared to ICT.”

Source: [IDEAYA Biosciences press release, ESMO 2026 data (2026)](https://media.ideayabio.com/2026-10-19-IDEAYA-Biosciences-and-Servier-Announce-Data-From-Three-Clinical-Trials-at-ESMO-2026-Supporting-the-Potential-of-Darovasertib-to-Become-a-Foundational-New-Therapy-for-Patients-Across-the-Treatment-Journey-of-Uveal-Melanoma)

<a id="topic-3.1.1.8.3-7"></a>

###### Overall survival status at the primary analysis

> “OS data is not yet mature; however, an early trend toward improved OS was observed with the darovasertib combination arm versus ICT. OS data will be presented at a future date”

Source: [Orloff et al. (2026a)](https://filecache.investorroom.com/mr5ir_ideayabio/616/OptimUM-02%20ASCO%20-%2026MAY2026.pdf)

> “Preliminary OS is also trending favorably.”

Source: [Orloff et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO.2026.44.17_suppl.LBA9503)

> “As noted in the topline results, data on overall survival (OS) was still immature as of the cutoff date, however, there was an early trend in OS improvement in the darovasertib combination arm relative to the ICT arm.”
> “IDEAYA will provide the next OS update as part of the pre-specified interim analysis.”

Source: [IDEAYA Biosciences press release, OptimUM-02 ASCO 2026 data (2026)](https://media.ideayabio.com/2026-06-01-IDEAYA-Biosciences-and-Servier-Provide-Complete-Data-from-Phase-2-3-Registrational-OptimUM-02-Trial-of-the-Darovasertib-Combination-in-First-Line-HLA-A2-01-Negative-Metastatic-Uveal-Melanoma-in-a-Late-Breaking-Oral-Presentation-at-ASCO)

<a id="topic-3.1.1.8.3-8"></a>

###### Secondary endpoint wording in the quarterly report for the first quarter of 2026, which differs from the releases and the presentation

> “In April 2026, we reported positive topline data from OptimUM-02, which demonstrated a statistically significant improvement in the primary endpoint of progression free survival, as well as a statistically significant improvement in the secondary endpoint of overall survival rate as assessed by blinded independent central review.”

Source: [IDEAYA Biosciences Form 10-Q, first quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1676725/000119312526206357/idya-20260331.htm)

<a id="heading-3.1.1.8.4"></a>

###### 3.1.1.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.1.8.4-1"></a>

###### Quality-of-life data not presented at the ASCO 2026 primary analysis

> “He noted that quality-of-life data were not presented, which he considered important given the chronic administration of two oral targeted agents.”

Source: [Barbor (2026)](https://ascopost.com/articles/2026/08-august/darovasertib-plus-crizotinib-may-set-new-first-line-standard-in-hla-a2-negative-metastatic-uveal-melanoma/)

<a id="heading-3.1.1.8.5"></a>

###### 3.1.1.8.5 Safety Results

<a id="topic-3.1.1.8.5-1"></a>

###### Treatment-related adverse events, phase 2a and 2b safety population of 239 and 100 participants (ASCO 2026 presentation)

> “Safety was evaluated in all patients (phase 2a and 2b) who received at least one dose of darovasertib 300 mg + crizotinib 200 mg or control”
> “Darovasertib 300mg + crizotinib 200 mg (N=239)”
> “Investigator’s Choice (control, N=100)”

Source: [Orloff et al. (2026a)](https://filecache.investorroom.com/mr5ir_ideayabio/616/OptimUM-02%20ASCO%20-%2026MAY2026.pdf)

| Outcome | Darovasertib plus crizotinib (N=239) | Investigator's choice (N=100) |
| --- | --- | --- |
| Any TRAE, n (%) | “235 (98.3)” | “89 (89.0)” |
| Grade 3 or 4 TRAE, n (%) | “97 (40.6)” | “37 (37.0)” |
| Grade 5 TRAE, n (%) | “1 (0.4)” | “1 (1.0)” |
| Treatment-related serious adverse event, n (%) | “22 (9.2)” | “25 (25.0)” |
| TRAE leading to withdrawal, row not naming a drug, n (%) | “2 (0.8)” | “5 (5.0)” |
| TRAE leading to darovasertib withdrawal, n (%) | “6 (2.5)” | Not applicable |
| TRAE leading to crizotinib withdrawal, n (%) | “24 (10.0)” | Not applicable |
| TRAE leading to investigator's choice withdrawal, n (%) | Not applicable | “19 (19.0)” |
| TRAE leading to darovasertib dose reduction, n (%) | “56 (23.4)” | Not applicable |
| TRAE leading to crizotinib dose reduction, n (%) | “63 (26.4)” | Not applicable |

Source: [Orloff et al. (2026a)](https://filecache.investorroom.com/mr5ir_ideayabio/616/OptimUM-02%20ASCO%20-%2026MAY2026.pdf)

> “Grade 5 SAEs: Hepatic failure in the darovasertib + crizotinib arm in a subject with extensive bulky liver metastases in both lobes considered unrelated by Sponsor; gastrointestinal hemorrhage in ICT arm”

Source: [Orloff et al. (2026a)](https://filecache.investorroom.com/mr5ir_ideayabio/616/OptimUM-02%20ASCO%20-%2026MAY2026.pdf)

| Most common TRAE of any grade (20% or more), darovasertib plus crizotinib arm | Darovasertib plus crizotinib (N=239), n (%) |
| --- | --- |
| Any TRAE | “235 ( 98.3)” |
| Diarrhea | “203 ( 84.9)” |
| Nausea | “179 ( 74.9)” |
| Peripheral edema | “160 ( 66.9)” |
| Vomiting | “119 ( 49.8)” |
| Dermatitis acneiform | “100 ( 41.8)” |
| Fatigue | “94 ( 39.3)” |
| Hypotension | “79 ( 33.1)” |
| Hypoalbuminemia, dysgeusia, and dizziness, each | “61 ( 25.5)” |
| Decreased appetite | “57 ( 23.8)” |

Source: [Orloff et al. (2026a)](https://filecache.investorroom.com/mr5ir_ideayabio/616/OptimUM-02%20ASCO%20-%2026MAY2026.pdf)

| Most common TRAE of any grade (20% or more), investigator's choice arm | Investigator's choice (N=100), n (%) |
| --- | --- |
| Any TRAE | “88 ( 88.0)” |
| Diarrhea | “29 ( 29.0)” |
| Alanine aminotransferase increased, aspartate aminotransferase increased, fatigue, and nausea, each | “25 ( 25.0)” |
| Pruritus | “24 ( 24.0)” |

Source: [Orloff et al. (2026a)](https://filecache.investorroom.com/mr5ir_ideayabio/616/OptimUM-02%20ASCO%20-%2026MAY2026.pdf)

| Grade 3 or 4 TRAE (2% or more), darovasertib plus crizotinib arm | Darovasertib plus crizotinib (N=239), n (%) |
| --- | --- |
| Any grade 3 or 4 adverse event | “97 ( 40.6)” |
| Diarrhea | “24 ( 10.0)” |
| Syncope | “17 (  7.1)” |
| Hypotension | “9 (  3.8)” |
| Nausea and peripheral edema, each | “7 (  2.9)” |
| Anemia | “6 (  2.5)” |

Source: [Orloff et al. (2026a)](https://filecache.investorroom.com/mr5ir_ideayabio/616/OptimUM-02%20ASCO%20-%2026MAY2026.pdf)

| Grade 3 or 4 TRAE (2% or more), investigator's choice arm | Investigator's choice (N=100), n (%) |
| --- | --- |
| Any grade 3 or 4 adverse event | “37 ( 37.0)” |
| Alanine aminotransferase increased and aspartate aminotransferase increased, each | “7 (  7.0)” |
| Diarrhea | “6 (  6.0)” |
| Hepatitis | “5 (  5.0)” |
| Colitis | “4 (  4.0)” |
| Lipase increased, autoimmune hepatitis, and amylase increased, each | “3 (  3.0)” |
| Tubulointerstitial nephritis, hypophysitis, and hyperthyroidism, each | “2 (  2.0)” |

Source: [Orloff et al. (2026a)](https://filecache.investorroom.com/mr5ir_ideayabio/616/OptimUM-02%20ASCO%20-%2026MAY2026.pdf)

<a id="topic-3.1.1.8.5-2"></a>

###### Treatment-emergent adverse events of any cause, ASCO 2026 abstract

> “The most common treatment emergent adverse events (AEs) for darova+crizo were diarrhea (89.5%), nausea (78.2%), peripheral edema (70.7%), & vomiting (53.6%). In the IC arm, these were nausea (41.4%), diarrhea (36.3%), fatigue (33.3%), AST & ALT elevation (31.1%).”
> “The most common Grade 3 or 4 AEs for darova + crizo were diarrhea (10.9%) & syncope (7.9%) and for IC, AST & ALT increase (8.1%), diarrhea (6.1%) & hepatitis (5.1%).”
> “One treatment related fatal AE occurred in each arm.”

Source: [Orloff et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO.2026.44.17_suppl.LBA9503)

<a id="topic-3.1.1.8.5-3"></a>

###### Treatment-related serious adverse events of 25.3% in the control arm, ASCO 2026 abstract

> “Treatment related serious AEs occurred in 9.2% and 25.3% on darova + crizo and IC respectively.”

Source: [Orloff et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO.2026.44.17_suppl.LBA9503)

<a id="topic-3.1.1.8.5-4"></a>

###### Treatment-related serious adverse events of 25.0% in the control arm and grade 3 or 4 events, ASCO 2026 release

> “Grade 3/4 treatment-related adverse events (TRAEs) occurred in 40.6% (97/239) of patients in the darovasertib combination arm compared to 37.0% (37/100) of patients in the ICT control arm.”
> “Treatment-related serious adverse events (TR-SAE) were 9.2% (22/239) and 25.0% (25/100) in the darovasertib combination and ICT arms, respectively.”
> “Median relative dose intensities of darovasertib and crizotinib were 91.0% and 77.1%, respectively, compared to 100% for the ICT arm.”

Source: [IDEAYA Biosciences press release, OptimUM-02 ASCO 2026 data (2026)](https://media.ideayabio.com/2026-06-01-IDEAYA-Biosciences-and-Servier-Provide-Complete-Data-from-Phase-2-3-Registrational-OptimUM-02-Trial-of-the-Darovasertib-Combination-in-First-Line-HLA-A2-01-Negative-Metastatic-Uveal-Melanoma-in-a-Late-Breaking-Oral-Presentation-at-ASCO)

<a id="topic-3.1.1.8.5-5"></a>

###### Grade 3 or higher adverse events in the topline release

> “The most common Grade 3+ treatment emergent adverse events included diarrhea, syncope, and hypotension. The treatment-related serious adverse events rate in the darovasertib combination was in the single-digit percent range.”

Source: [IDEAYA Biosciences press release, OptimUM-02 topline results (2026)](https://media.ideayabio.com/2026-04-13-IDEAYA-Biosciences-and-Servier-Announce-Positive-Topline-Results-from-Phase-2-3-Registrational-Trial-OptimUM-02-of-Darovasertib-in-Combination-with-Crizotinib-in-First-line-HLA-A-02-01-Negative-Metastatic-Uveal-Melanoma)

<a id="topic-3.1.1.8.5-6"></a>

###### Management of hypotension and syncope as reported from the ASCO 2026 presentation

> “Dr. Orloff discussed hypotension and syncope as distinctive toxicities associated with protein kinase C inhibition, noting that they were managed with hydration, holding blood pressure medications when appropriate, and a 7-day darovasertib run-in before crizotinib was added.”
> “In the investigator’s choice arm, the toxicity profile largely reflected checkpoint inhibitor therapy, with events including diarrhea, liver enzyme elevations, hepatitis, colitis, and endocrinopathies.”

Source: [Barbor (2026)](https://ascopost.com/articles/2026/08-august/darovasertib-plus-crizotinib-may-set-new-first-line-standard-in-hla-a2-negative-metastatic-uveal-melanoma/)

<a id="heading-3.1.1.9"></a>

##### 3.1.1.9 Study Limitations

<a id="topic-3.1.1.9-1"></a>

###### Summary

OptimUM-02 is open label, with no masking. The primary analysis was reported at a median follow-up of 7.4 months; OS, the phase 3 primary endpoint, was not mature, and no OS estimate has been reported. The efficacy population of 313 participants is the intent-to-treat population of the phase 2b portion, which the topline release describes as enrolled in the phase 2b/3 portion; the safety analyses use different denominators, 338 participants in the ASCO 2026 abstract and 239 and 100 participants from phases 2a and 2b in the presentation. Reported enrollment is 435 participants in the full enrollment release and 437 in the annual report for 2025.

The comparator was investigator's choice: 79 participants (76.7%) received ipilimumab plus nivolumab, 24 (23.3%) pembrolizumab, and none dacarbazine (the topline release gives 78 and 25), and the EU trial record restricts dacarbazine to settings where immunotherapy is deemed likely to cause irreversible serious adverse events. No post-baseline response assessment was available for 24 participants (23.3%) in the control arm and 12 (5.7%) in the combination arm; 17 control participants withdrew consent before treatment. More participants in the combination arm had ECOG performance status 1 (22.9% vs 15.5%) and a largest metastatic lesion of 8.1 cm or more (8.6% vs 4.9%). Subgroups with LDH 2 times the ULN or higher, target lesion 8 cm or larger, or extrahepatic-only metastases had small numbers of participants and 95% confidence intervals that included the null value. Quality of life by the EORTC QLQ-C30 was a stated endpoint, and quality-of-life data were not presented at ASCO 2026. TRAEs led to dose reduction of darovasertib in 23.4% and of crizotinib in 26.4% of participants.

The sources conflict on several figures: the quarterly report for the first quarter of 2026 describes a statistically significant improvement in OS rate, while the presentation and releases describe OS as immature; any-grade TRAEs in the control arm are 89 (89.0%) in the summary table and 88 (88.0%) in the table of common events; treatment-related serious adverse events in the control arm are 25.0% in the presentation and release and 25.3% in the abstract; and one treatment-related fatal adverse event is reported in each arm while the grade 5 hepatic failure in the combination arm is described as considered unrelated by the sponsor.

Source: [ClinicalTrials.gov NCT05987332](https://clinicaltrials.gov/study/NCT05987332); [Orloff et al. (2026a)](https://filecache.investorroom.com/mr5ir_ideayabio/616/OptimUM-02%20ASCO%20-%2026MAY2026.pdf); [Orloff et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO.2026.44.17_suppl.LBA9503); [IDEAYA Biosciences press release, OptimUM-02 topline results (2026)](https://media.ideayabio.com/2026-04-13-IDEAYA-Biosciences-and-Servier-Announce-Positive-Topline-Results-from-Phase-2-3-Registrational-Trial-OptimUM-02-of-Darovasertib-in-Combination-with-Crizotinib-in-First-line-HLA-A-02-01-Negative-Metastatic-Uveal-Melanoma); [IDEAYA Biosciences press release, OptimUM-02 ASCO 2026 data (2026)](https://media.ideayabio.com/2026-06-01-IDEAYA-Biosciences-and-Servier-Provide-Complete-Data-from-Phase-2-3-Registrational-OptimUM-02-Trial-of-the-Darovasertib-Combination-in-First-Line-HLA-A2-01-Negative-Metastatic-Uveal-Melanoma-in-a-Late-Breaking-Oral-Presentation-at-ASCO); [IDEAYA Biosciences press release, OptimUM-02 full enrollment (2025)](https://media.ideayabio.com/2025-12-11-IDEAYA-Biosciences-Completes-Targeted-Full-Enrollment-in-Randomized-Pivotal-Phase-2-3-Trial-OptimUM-02-of-Darovasertib-in-Combination-with-Crizotinib-in-First-line-HLA-A2-Negative-Metastatic-Uveal-Melanoma); [IDEAYA Biosciences Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1676725/000119312526054533/idya-20251231.htm); [Piperno-Neumann et al. (2026c)](https://www.ideayabio.com/sites/default/files/publications/2026-11/ESMO-2026-Piperno-Neumann-OptimUM-02.pdf); [EU CTIS 2023-506686-66-01](https://euclinicaltrials.eu/ctis-public-api/retrieve/2023-506686-66-01); [Barbor (2026)](https://ascopost.com/articles/2026/08-august/darovasertib-plus-crizotinib-may-set-new-first-line-standard-in-hla-a2-negative-metastatic-uveal-melanoma/); [IDEAYA Biosciences Form 10-Q, first quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1676725/000119312526206357/idya-20260331.htm)

<a id="topic-3.1.1.9-2"></a>

###### Small subgroups with wide confidence intervals, ESMO 2026 poster

> “For select subgroup categories (i.e., LDH ≥2 × ULN, target lesion ≥8 cm, and extrahepatic-only metastases), the small number of participants resulted in wide 95% confidence intervals that included the null value, limiting the interpretation of treatment effect estimates in these categories”

Source: [Piperno-Neumann et al. (2026c)](https://www.ideayabio.com/sites/default/files/publications/2026-11/ESMO-2026-Piperno-Neumann-OptimUM-02.pdf)

<a id="topic-3.1.1.9-3"></a>

###### Discussant comments on immature overall survival, baseline imbalance, dose reductions, and open questions

> “He also pointed out that the progression-free survival benefit was seen despite slight baseline imbalances favoring the control arm.”
> “On safety, Dr. Lutzky said grade 3 and 4 toxicity rates were comparable to those seen with current therapies and that discontinuation rates remained relatively low, although about one-quarter of patients required dose reductions.”
> “He noted that several questions remain, including whether progression-free survival will translate into overall survival, how available treatments should be sequenced, whether targeted therapy can be safely combined with liver-directed approaches or immunotherapy, and whether these benefits can be moved into the adjuvant setting.”

Source: [Barbor (2026)](https://ascopost.com/articles/2026/08-august/darovasertib-plus-crizotinib-may-set-new-first-line-standard-in-hla-a2-negative-metastatic-uveal-melanoma/)

<a id="heading-3.1.2"></a>

#### 3.1.2 OptimUM-01

<a id="heading-3.1.2.1"></a>

##### 3.1.2.1 Objective

<a id="topic-3.1.2.1-1"></a>

###### First-line cohort: safety and efficacy of darovasertib plus crizotinib in the phase 2 expansion

> “To report the safety and efficacy results from the phase II dose expansion portion of the OptimUM-01 trial for patients with metastatic uveal melanoma (mUM) treated in the first-line setting with the combination of the first-in-class, oral, targeted protein kinase C inhibitor darovasertib plus the MET-inhibitor crizotinib.”
> “Here, we present phase 2 results in first-line patients with mUM treated with darovasertib 300 mg twice a day and crizotinib 200 mg twice a day.”

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802)

<a id="topic-3.1.2.1-2"></a>

###### Registry title and purpose of the basket study

> “A Phase 1/2 Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions”
> “This is a Phase 1/2, multi-center, open-label basket study designed to evaluate the safety and anti-tumor activity of IDE196 in patients with solid tumors harboring GNAQ or GNA11 (GNAQ/11) mutations or PRKC fusions, including metastatic uveal melanoma (MUM), cutaneous melanoma, colorectal cancer, and other solid tumors.”
> “Phase 1 (dose escalation - crizotinib combination) will assess safety, tolerability and pharmacokinetics of IDE196 and crizotinib via standard dose escalation scheme and determine the recommended Phase 2 dose.”

Source: [ClinicalTrials.gov NCT03947385](https://clinicaltrials.gov/study/NCT03947385)

<a id="topic-3.1.2.1-3"></a>

###### HLA-A∗02:01-positive expansion: analysis of participants treated with darovasertib plus crizotinib

> “This analysis focuses on the phase 2 expansion in HLA-A02:01-positive patients with mUM treated with darova+criz”

Source: [McKean et al. (2026a)](https://www.ideayabio.com/sites/default/files/publications/2026-11/ESMO-2026-McKean-OptimUM-01.pdf)

<a id="topic-3.1.2.1-4"></a>

###### First-line and pretreated cohorts: evaluation of the combination

> “This phase 1/2 study evaluated the combination in first line (1L) and pretreated MUM.”

Source: [McKean et al. (2023)](https://www.annalsofoncology.org/article/S0923-7534%2823%2903052-1/fulltext)

<a id="heading-3.1.2.2"></a>

##### 3.1.2.2 Location and Study Date

<a id="topic-3.1.2.2-1"></a>

###### Registry study dates

| Study characteristic | Quoted record |
| --- | --- |
| Study start (actual) | “2019-06-28” |
| Primary completion (estimated) | “2027-01-29” |
| Study completion (estimated) | “2027-06-15” |

Source: [ClinicalTrials.gov NCT03947385](https://clinicaltrials.gov/study/NCT03947385)

<a id="topic-3.1.2.2-2"></a>

###### Registry study sites

| Country | Quoted site |
| --- | --- |
| United States | “UCLA Medical Center” |
| United States | “San Francisco Oncology Associates” |
| United States | “SCRI - Denver” |
| United States | “University of Iowa” |
| United States | “Cancer Hematology Centers Western Michigan” |
| United States | “Columbia University Medical Center - Herbert Irving Pavilion” |
| United States | “Duke University Medical Center” |
| United States | “University of Cincinnati Cancer Center” |
| United States | “The Cleveland Clinic Foundation” |
| United States | “Sidney Kimmel Cancer Center at Thomas Jefferson University” |
| United States | “The Sarah Cannon Research Institute/Tennessee Oncology” |
| United States | “The University of Texas MD Anderson Cancer Center” |
| Australia | “Westmead Hospital” |
| Canada | “Princess Margaret Cancer Centre” |

Source: [ClinicalTrials.gov NCT03947385](https://clinicaltrials.gov/study/NCT03947385)

<a id="topic-3.1.2.2-3"></a>

###### First-line cohort publication: enrolling centers

| Country | Quoted institution |
| --- | --- |
| United States | “Sarah Cannon Research Institute Nashville, TN” |
| United States | “MD Anderson, Houston, TX” |
| United States | “Thomas Jefferson University Hospital, Philadelphia, PA” |
| United States | “Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA” |
| United States | “Duke University Medical Center, Durham, NC” |
| United States | “California Pacific Medical Center Research Institute, San Francisco, CA” |
| United States | “University of Cincinnati Medical Center, Cincinnati, OH” |
| United States | “Cancer and Hematology Centers of Western Michigan, Grand Rapids, MI” |
| United States | “Cleveland Clinic, Cleveland, OH” |
| United States | “Sarah Cannon Research Institute at Healthone Denver, Denver, CO” |
| United States | “Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA” |
| United States | “Honor Health Research Institute, Scottsdale, AZ” |
| United States | “Florida Cancer Specialist—North, FL” |
| United States | “Florida Cancer Specialist—South, FL” |
| United States | “St Joseph Mosaic Life Care, St Joseph, MO” |
| United States | “Goshen Health Center for Cancer Care, Goshen, IN” |
| United States | “Columbia University Medical Center, New York Presbyterian Hospital, New York, NY” |
| United States | “The University of Texas MD Anderson Cancer Center, TX” |
| Australia | “Westmead and Blacktown Hospitals, University of Sydney and Melanoma Institute Australia” |
| Australia | “University of Queensland, Brisbane” |
| Canada | “Princess Margaret Cancer Centre, Departments of Medicine and Immunology, University of Toronto, Toronto” |

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802)

<a id="topic-3.1.2.2-4"></a>

###### First-line cohort: data cutoff of May 28, 2025

> “As of the data cutoff for the analysis (May 28, 2025), the mean duration of exposure was 10 months for both darovasertib and crizotinib.”

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802)

<a id="topic-3.1.2.2-5"></a>

###### HLA-A∗02:01-positive expansion: data extract date of March 23, 2026

> “Herein, we evaluated darova+criz among HLA-A02:01-positive patients enrolled in the expansion phase of the OptimUM-01 study (Data extract date of March 23, 2026)”

Source: [McKean et al. (2026a)](https://www.ideayabio.com/sites/default/files/publications/2026-11/ESMO-2026-McKean-OptimUM-01.pdf)

> “The ESMO update focuses on the Phase 2 expansion results from OptimUM-01 in HLA-A*02:01-positive mUM patients as of a cutoff date of March 23, 2026.”

Source: [IDEAYA Biosciences press release, ESMO 2026 data (2026)](https://media.ideayabio.com/2026-10-19-IDEAYA-Biosciences-and-Servier-Announce-Data-From-Three-Clinical-Trials-at-ESMO-2026-Supporting-the-Potential-of-Darovasertib-to-Become-a-Foundational-New-Therapy-for-Patients-Across-the-Treatment-Journey-of-Uveal-Melanoma)

<a id="topic-3.1.2.2-6"></a>

###### First-line and pretreated cohorts: data cutoff of August 22, 2023

> “Reported data are preliminary and based on investigator review from an unlocked database for 68 patients as of the data analyses cutoff date of August 22, 2023.”

Source: [IDEAYA Biosciences press release, ESMO 2023 phase 2 results (2023)](https://media.ideayabio.com/2023-10-23-IDEAYA-Announces-Top-Line-Phase-2-Results-at-ESMO-2023-of-Darovasertib-and-Crizotinib-Combo-in-MUM,-and-Clinical-Efficacy-Updates-for-Neoadjuvant-UM,-GNAQ-11-Cutaneous-Melanoma,-and-Synthetic-Lethality-Pipeline)

<a id="heading-3.1.2.3"></a>

##### 3.1.2.3 Study Design

<a id="topic-3.1.2.3-1"></a>

###### First-line cohort: phase 1/2, multicenter, open-label, dose-escalation and expansion design

> “OptimUM-01 was a phase I/II, multicenter, open-label, dose-escalation and expansion study, which evaluated monotherapy darovasertib and combination cohorts that included crizotinib in patients with mUM irrespective of HLA status (Appendix Fig A2).”
> “This analysis focuses on the phase 2 expansion in previously untreated patients who received darovasertib 300 mg twice a day in combination with crizotinib 200 mg twice a day.”
> “Results from other dosing cohorts of this trial will be published separately.”
> “The trial was approved by the institutional review board or independent ethics committee at each center, and all participants provided written informed consent.”

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802)

<a id="topic-3.1.2.3-2"></a>

###### Registry design: nonrandomized, open-label, sequential assignment

| Study characteristic | Quoted record |
| --- | --- |
| Other study ID number | “IDE196-001” |
| Primary purpose | “Treatment” |
| Allocation | “Non-Randomized” |
| Interventional model | “Sequential Assignment” |
| Masking | “None (Open Label)” |

Source: [ClinicalTrials.gov NCT03947385](https://clinicaltrials.gov/study/NCT03947385)

<a id="topic-3.1.2.3-3"></a>

###### Registry: crizotinib combination dose optimization, crizotinib monotherapy cohort, and enrollment status by cohort

> “Evaluation of safety and efficacy across multiple doses may be explored in the dose optimization part of the study.”
> “Crizotinib monotherapy with crossover to combination cohort may be assessed for safety and to show the contribution of each study drug to anti-tumor activity.”
> “As of Protocol Amendment 10, Phase 1, Phase 2 dose expansion in IDE196 monotherapy, and Phase 2 dose expansion of IDE196 in combination with binimetinib have been fully enrolled. There were no patients enrolled in the crizotinib monotherapy cohorts.”

Source: [ClinicalTrials.gov NCT03947385](https://clinicaltrials.gov/study/NCT03947385)

<a id="topic-3.1.2.3-4"></a>

###### Registry: enrolling crizotinib combination expansion cohort of HLA-A∗02:01-positive participants with nested pharmacokinetic substudies

> “MUM patients (previously treated or treatment naive) with human leukocyte antigen (HLA)-A*02:01 positive status.”
> “Includes a nested PK sub-study with Pravastatin (~22 participants) to evaluate the impact of pravastatin PK profiles after continuous dosing of IDE196.”
> “Includes a nested PK Cocktail DDI sub-study (~15 participants) to evaluate the impact on the PK of bupripion, repaglinide, flurbiprofen, omeprazole, midazolam, dabigatran etexilate, and the exposures of the OAT3 biomarker PDA by IDE196 in combination with crizotinib.”

Source: [ClinicalTrials.gov NCT03947385](https://clinicaltrials.gov/study/NCT03947385)

<a id="topic-3.1.2.3-5"></a>

###### Combination dose escalation: 3 + 3 design followed by expansion

> “Dose escalation used a 3 + 3 design with 3 escalation cohorts, followed by expansion at 300 mg BID Daro + 200 mg BID Crizo.”

Source: [McKean et al. (2023)](https://www.annalsofoncology.org/article/S0923-7534%2823%2903052-1/fulltext)

<a id="topic-3.1.2.3-6"></a>

###### HLA-A∗02:01-positive expansion: study design as described in the poster

> “OptimUM-01 is a phase 1/2, multi-center, open-label, dose escalation and expansion study including patients with solid tumors harboring GNAQ/11 mutations”

Source: [McKean et al. (2026a)](https://www.ideayabio.com/sites/default/files/publications/2026-11/ESMO-2026-McKean-OptimUM-01.pdf)

<a id="heading-3.1.2.4"></a>

##### 3.1.2.4 Eligibility Criteria

<a id="topic-3.1.2.4-1"></a>

###### First-line cohort: key eligibility criteria

> “Patients were required to be age 18 years or older and have a histologic or cytologic confirmation of uveal melanoma. Eligible patients had metastatic disease that was measurable as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, an Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1, and adequate organ function. This analysis is specific to individuals who had not received previous therapy for mUM.”

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802)

<a id="topic-3.1.2.4-2"></a>

###### Inclusion criteria, including documentation required for treatment-naive HLA-A∗02:01-positive participants

> “Patient must be age 18 years and older and able to provide written informed consent”
> “Metastatic uveal melanoma: histologic or cytologic confirmation of metastatic uveal melanoma. Metastatic disease may be treatment-naïve or have progressed on or after most recent therapy. If the most recent therapy was an immune-oncology agent, progressive disease must be confirmed.”
> “If a patient is treatment-naïve and human leukocyte antigen (HLA)-A*02:01–positive,”
> “documentation is required to provide rationale why treatment with tebentafusp is not the ideal first-line treatment approach or of the patient's intolerance to tebentafusp.”
> “To be enrolled in the HLA-A*02:01–positive cohort, HLA status must be documented by test results from a College of American Pathologists/ Clinical Laboratory Improvement Amendments-certified laboratory.”
> “Eastern Cooperative Oncology Group performance status ≤1 and expected life expectancy of >3 months”
> “Adequate contraceptive measures for nonsterilized male and female patients of childbearing potential”

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802)

<a id="topic-3.1.2.4-3"></a>

###### Additional inclusion criteria for the crizotinib combination

> “Prior chemotherapy other therapies as applicable or major surgeries must have been completed at least 4 weeks before initiation of crizotinib”
> “Patients with preexisting peripheral neuropathy can be included if it is grade 1 or lower, before initiation of crizotinib”
> “Accessible lesion(s) that permit a total of at least two biopsies without unacceptable risk of a significant procedural complication.”

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802)

<a id="topic-3.1.2.4-4"></a>

###### Exclusion criteria

> “Previous treatment with a protein kinase C inhibitor”
> “Known microsatellite instability-high/deficient mismatch repair tumors that have not previously received immune checkpoint inhibitors”
> “Known symptomatic brain metastases”
> “Adverse events from prior anticancer therapy that have not resolved”
> “Known acquired immunodeficiency syndrome (AIDS)–related illness, hepatitis B virus, or hepatitis C virus”
> “Prior gastrectomy or upper bowel removal or any other gastrointestinal disorder or defect”
> “Treatment with prohibited medications that cannot be discontinued before study entry”
> “For patients receiving darovasertib powder-in-capsule formulation or crizotinib, allergy to mammalian meat products and gelatin”

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802)

<a id="topic-3.1.2.4-5"></a>

###### Additional exclusion criteria for the crizotinib combination

> “Prior therapy directly targeting ALK, MET, or ROS1”
> “History of pneumonitis or interstitial lung disease”
> “History of thromboembolic or cerebrovascular events ≤12 weeks before first dose of study treatment”

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802)

<a id="topic-3.1.2.4-6"></a>

###### Registry: exclusion criteria of the pravastatin pharmacokinetic substudy

> “Taken any dose of statin or inhibitor of organic anion transporting polypeptide within 7 days prior to enrollment in the study and cannot refrain from them through C2D1”

Source: [ClinicalTrials.gov NCT03947385](https://clinicaltrials.gov/study/NCT03947385)

<a id="topic-3.1.2.4-7"></a>

###### HLA-A∗02:01-positive expansion: eligibility criteria

> “Eligibility criteria included RECIST v1.1 measurable disease, ECOG status 0-1, and adequate organ function”

Source: [McKean et al. (2026a)](https://www.ideayabio.com/sites/default/files/publications/2026-11/ESMO-2026-McKean-OptimUM-01.pdf)

<a id="topic-3.1.2.4-8"></a>

###### First-line and pretreated cohorts: eligibility criteria

> “Eligibility included RECIST 1.1 measurable disease, ECOG 0-1 and adequate organ function.”

Source: [McKean et al. (2023)](https://www.annalsofoncology.org/article/S0923-7534%2823%2903052-1/fulltext)

<a id="heading-3.1.2.5"></a>

##### 3.1.2.5 Treatment

<a id="topic-3.1.2.5-1"></a>

###### First-line cohort: dose selection, darovasertib run-in, and continuous 28-day cycles

> “The recommended dose of crizotinib 200 mg twice a day used in combination with darovasertib 300 mg twice a day for the phase 2 expansion was selected based on a favorable benefit-risk profile from the earlier dose-escalation and dose-optimization portion of the study.”
> “The first treatment cycle had a 7-day darovasertib treatment run-in followed by continuous dosing of the combination over a 28-day cycle.”
> “Patients remained on treatment until discontinuation due to toxicity or until disease progression and received tumor assessments every 8 weeks; treatment beyond progression was permitted for patients who were deriving clinical benefit.”

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802)

<a id="topic-3.1.2.5-2"></a>

###### Registry interventions: oral twice-daily dosing in 28-day cycles

> “IDE196 dosed orally, twice daily for each 28-day cycle”
> “Crizotinib dosed orally, twice daily for each 28-day cycle”

Source: [ClinicalTrials.gov NCT03947385](https://clinicaltrials.gov/study/NCT03947385)

<a id="topic-3.1.2.5-3"></a>

###### First-line and pretreated cohorts: expansion dose of darovasertib 300 mg and crizotinib 200 mg twice a day

> “The reported Phase 2 clinical data are based on evaluable first-line and any-line patients enrolled in the darovasertib and crizotinib combination study at the expansion dose of 300 mg twice-a-day darovasertib and 200 mg twice-a-day crizotinib as of September 22, 2022.”

Source: [IDEAYA Biosciences press release, ESMO 2023 phase 2 results (2023)](https://media.ideayabio.com/2023-10-23-IDEAYA-Announces-Top-Line-Phase-2-Results-at-ESMO-2023-of-Darovasertib-and-Crizotinib-Combo-in-MUM,-and-Clinical-Efficacy-Updates-for-Neoadjuvant-UM,-GNAQ-11-Cutaneous-Melanoma,-and-Synthetic-Lethality-Pipeline)

<a id="topic-3.1.2.5-4"></a>

###### Selection of the combination expansion dose for potential registrational studies

> “IDEAYA has selected a darovasertib and crizotinib combination expansion dose to support potential registrational studies.”

Source: [IDEAYA Biosciences press release, phase 2 expansion dose data in pretreated metastatic uveal melanoma (2021)](https://media.ideayabio.com/2021-12-07-IDEAYA-Reports-Clinical-Data-from-Phase-2-Expansion-Dose-of-Darovasertib-and-Crizotinib-Synthetic-Lethal-Combination-in-Heavily-Pre-Treated-Metastatic-Uveal-Melanoma)

<a id="heading-3.1.2.6"></a>

##### 3.1.2.6 Study Outcomes

<a id="heading-3.1.2.6.1"></a>

###### 3.1.2.6.1 Rationale for Using RECIST v1.1 Objective Response Rate as the Primary Endpoint

<a id="topic-3.1.2.6.1-1"></a>

###### First-line cohort: investigator-assessed RECIST v1.1 response and imaging schedule

> “Tumor response was assessed by radiologic imaging determined by the investigator according to RECIST, version 1.1.”
> “Tumor assessments were performed at Cycle 3 Day 1 (±7 days) and every two cycles thereafter (±7 days).”
> “For patients who remained on study for longer than 13 cycles, tumor imaging evaluations were performed on Cycle 16 Day 1 (±7 days), and every three cycles thereafter until disease progression (±7 days).”
> “Safety was evaluated by ongoing monitoring of AEs, clinical laboratory tests, electrocardiograms, and changes in vital signs.”

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802)

<a id="topic-3.1.2.6.1-2"></a>

###### First-line cohort: end points, with overall survival as an exploratory end point

> “Study end points included safety, objective response rate (ORR), duration of response (DOR), disease control rate (DCR), progression-free survival (PFS), and overall survival (OS).”
> “Study design. Overall survival is an exploratory end point in this trial.”

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802)

<a id="topic-3.1.2.6.1-3"></a>

###### First-line cohort: definitions of objective response, disease control, and duration of response

> “ORR was defined as the proportion of patients with best response of complete response (CR) or partial response (PR) as defined by RECIST, version 1.1. Confirmation of response was required.”
> “DCR was defined as the proportion of patients who have achieved a best response of CR or PR, or stable disease (SD) lasting for at least 8 weeks after the first assessment of CR, PR, or SD.”
> “DOR was defined as the time of first occurrence of a documented response (CR or PR) until the date of disease progression per RECIST 1.1 or death, whichever occurred first.”

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802)

<a id="topic-3.1.2.6.1-4"></a>

###### First-line cohort: definitions of progression-free survival, overall survival, and molecular response

> “PFS was defined as the number of days from first day of treatment to the date of first documented disease progression or date of death, whichever occurred first, for patients who received at least one dose of study treatment.”
> “OS was defined as the number of days from first day of treatment to the date of death.”
> “A confirmed molecular partial response was defined as a ≥50% reduction from baseline in the molecular biomarker (cfDNA), confirmed by a second measurement obtained at least 4 weeks after the initial response.”

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802)

<a id="topic-3.1.2.6.1-5"></a>

###### Registry primary outcomes

| Outcome | Quoted measure | Quoted time frame |
| --- | --- | --- |
| Dose-limiting toxicity | “Determine DLT of IDE196 as monotherapy, in combination with Binimetinib, or in combination with Crizotinib” | “28 days following first dose of IDE196 as monotherapy, in combination with Binimetinib, or in combination with Crizotinib” |
| Adverse events | “Safety and tolerability of IDE196 either as monotherapy, in combination with Binimetinib, or in combination with Crizotinib” | “Approx. 8 months” |
| Maximum tolerated dose | “Determine MTD of IDE196 as monotherapy, in combination with Binimetinib, or in combination with Crizotinib” | “28 days following first dose of IDE196 as monotherapy, in combination with Binimetinib, or in combination with Crizotinib” |
| Recommended phase 2 dose | “Determine RP2D of IDE196 as monotherapy, in combination with Binimetinib, or in combination with Crizotinib” | “Approx. 6 months” |
| Objective response rate in dose expansion | “Overall Response Rate (ORR) of IDE196 monotherapy, in combination with Binimetinib, and in combination with Crizotinib in Dose Expansion cohorts by Investigator response assessment” | “Approx. 8 months” |
| Duration of response in dose expansion | “Duration of Response (DOR) of IDE196 monotherapy, in combination with Binimetinib, and in combination with Crizotinib in Dose Expansion cohorts by Investigator response assessment” | “Approx. 8 months” |

Source: [ClinicalTrials.gov NCT03947385](https://clinicaltrials.gov/study/NCT03947385)

<a id="topic-3.1.2.6.1-6"></a>

###### Registry secondary outcomes

| Outcome | Quoted measure | Quoted time frame |
| --- | --- | --- |
| Progression-free survival | “Progression Free Survival (PFS) of IDE196 monotherapy, in combination with Binimetinib, and in combination with Crizotinib in Dose Expansion cohorts by Investigator response assessment” | “Approx. 18 months” |
| Objective response rate by prior treatment status | “Overall Response Rate (ORR) of IDE196 monotherapy, in combination with Binimetinib, and in combination with Crizotinib in Dose Expansion cohorts and by prior treatment status (pretreated or treatment naive) by Investigator response assessment” | “Approx. 18 months” |
| Duration of response by prior treatment status | “Duration of Response (DOR) of IDE196 monotherapy, in combination with Binimetinib, and in combination with Crizotinib in Dose Expansion cohorts by prior treatment status (pretreated or treatment naive) by Investigator response assessment” | “Approx. 18 months” |
| Disease control rate | “Disease Control Rate (DCR) by Investigator” | “Approx. 18 months” |

Source: [ClinicalTrials.gov NCT03947385](https://clinicaltrials.gov/study/NCT03947385)

<a id="topic-3.1.2.6.1-7"></a>

###### HLA-A∗02:01-positive expansion: end points

> “Endpoints included PFS, OS, and safety as well as objective response rate (ORR), duration of response (DOR), and disease control rate (DCR)”

Source: [McKean et al. (2026a)](https://www.ideayabio.com/sites/default/files/publications/2026-11/ESMO-2026-McKean-OptimUM-01.pdf)

<a id="topic-3.1.2.6.1-8"></a>

###### FDA guidance: objective response rate as a direct measure of antitumor activity evaluable in a single-arm study

> “ORR is defined as the proportion of patients with tumor size reduction of a predefined amount and for a minimum time period.”
> “Generally, the FDA has defined ORR as the sum of partial responses plus CRs.  When defined in this manner, ORR is a direct measure of a drug antitumor activity, which can be evaluated in a single-arm study.”
> “Stable disease should not be a component of ORR.  Stable disease can reflect the natural history of disease, whereas tumor reduction is a direct therapeutic effect.”
> “The significance of ORR is assessed by its magnitude and duration, and the percentage of CRs.”

Source: [FDA guidance, Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics (2018)](https://www.fda.gov/media/71195/download)

<a id="topic-3.1.2.6.1-9"></a>

###### FDA guidance: single-arm studies, accelerated approval, and time-to-event end points

> “In settings where there is no available therapy and where major tumor regressions can be presumed to be attributed to the tested drug, the FDA has sometimes accepted ORR and response duration observed in single-arm studies as substantial evidence supporting accelerated approval.”
> “Single-arm trials do not adequately characterize time-to-event endpoints such as overall survival, DFS (and EFS), TTP, or PFS.”
> “Because ORR is directly attributable to drug effect, single-arm trials conducted in patients with refractory tumors where no available therapy exists provide an accurate assessment of ORR.”

Source: [FDA guidance, Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics (2018)](https://www.fda.gov/media/71195/download)

<a id="topic-3.1.2.6.1-10"></a>

###### IDE196 monotherapy: FDA End-of-Phase 1 feedback on a single-arm design with response rate as the primary endpoint

> “FDA EOP1 meeting minutes indicate that the proposed single-arm Phase 2 IDE196 clinical trial may be adequate to support a new drug application (NDA) seeking Accelerated Approval of IDE196 monotherapy for the treatment of MUM”
> “This Phase 2 clinical trial will target enrollment of 60 evaluable MUM patients with the primary endpoint of overall response rate (ORR) as determined by blinded independent central review (BICR)”

Source: [IDEAYA Biosciences press release, End-of-Phase 1 meeting with FDA (2019)](https://media.ideayabio.com/2019-10-31-IDEAYA-Biosciences-Reports-End-of-Phase-1-Meeting-with-FDA-for-IDE196-Confirms-Acceptability-of-Single-Arm-Trial-Design-for-Potential-Phase-2-Registration-Enabling-Study-in-Metastatic-Uveal-Melanoma)

<a id="heading-3.1.2.7"></a>

##### 3.1.2.7 Statistical Analysis Description

<a id="heading-3.1.2.7.1"></a>

###### 3.1.2.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.2.7.1-1"></a>

###### First-line cohort: 44 participants enrolled and treated, 41 evaluable for response

> “There were 44 patients with no prior systemic therapy for mUM who were enrolled and received darovasertib-crizotinib.”
> “The waterfall plot with a percent change from baseline in the sum of longest diameters for each evaluable patient (n = 41) is displayed in Figure 1.”

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802)

<a id="topic-3.1.2.7.1-2"></a>

###### Registry: estimated enrollment

| Study characteristic | Quoted record |
| --- | --- |
| Enrollment (estimated), all cohorts of the basket study | “336” |

Source: [ClinicalTrials.gov NCT03947385](https://clinicaltrials.gov/study/NCT03947385)

<a id="topic-3.1.2.7.1-3"></a>

###### Pretreated cohort, data cutoff of November 25, 2021: target enrollment of the combination arm and participants enrolled at the expansion dose

> “The companies have agreed to support a target enrollment of approximately 40 patients into the ongoing Phase 1/2 clinical combination arm in MUM.”
> “At the time of the data and analyses cutoff on November 25, 2021, twenty-two (22) heavily pre-treated (91% with prior therapies, and 59% with 2 or more prior therapies) MUM patients had enrolled in the darovasertib and crizotinib combination arm at the expansion dose, with sixteen (16) evaluable patients who have received one or more tumor scans and 6 patients who are awaiting their 1st tumor scan.”

Source: [IDEAYA Biosciences press release, phase 2 expansion dose data in pretreated metastatic uveal melanoma (2021)](https://media.ideayabio.com/2021-12-07-IDEAYA-Reports-Clinical-Data-from-Phase-2-Expansion-Dose-of-Darovasertib-and-Crizotinib-Synthetic-Lethal-Combination-in-Heavily-Pre-Treated-Metastatic-Uveal-Melanoma)

<a id="topic-3.1.2.7.1-4"></a>

###### First-line and pretreated cohorts, data cutoff of March 8, 2023: safety population of 68 and per-protocol efficacy population of 63 participants

> “At 08Mar2023 data cut-off, of 68 MUM pts treated at the expansion dose (safety population (SP)) as of September 2022, 63 were evaluable for response (per-protocol efficacy population (PPEP)).”

Source: [McKean et al. (2023)](https://www.annalsofoncology.org/article/S0923-7534%2823%2903052-1/fulltext)

<a id="topic-3.1.2.7.1-5"></a>

###### HLA-A∗02:01-positive expansion: 101 participants treated

> “Overall, 101 HLA-A02:01-positive patients were treated (Table 1), with a median follow-up of 10.4 months for overall survival”

Source: [McKean et al. (2026a)](https://www.ideayabio.com/sites/default/files/publications/2026-11/ESMO-2026-McKean-OptimUM-01.pdf)

<a id="heading-3.1.2.7.2"></a>

###### 3.1.2.7.2 Description of Analysis Sets

<a id="topic-3.1.2.7.2-1"></a>

###### First-line cohort: safety population and efficacy-evaluable population

> “Analysis populations included the safety population, defined as all patients who received at least one dose of the study drug. Patients who received at least one dose of the study drug and had at least one postbaseline tumor assessment were considered efficacy-evaluable (ie, efficacy evaluable population) for ORR, disease control rate (DCR), and duration of response (DOR). PFS and OS were reported for the full safety population.”

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802)

<a id="topic-3.1.2.7.2-2"></a>

###### First-line cohort: three participants excluded from the response analysis

> “Two patients who discontinued treatment before postbaseline tumor assessments (one due to AE of sudden death and another due to patient decision) and one ongoing patient who had not yet had a postbaseline tumor assessment were excluded from this analysis.”

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802)

<a id="topic-3.1.2.7.2-3"></a>

###### First-line cohort: descriptive analysis without formal hypothesis testing

> “There was no formal hypothesis testing prespecified for this analysis. All results were summarized descriptively.”
> “Time-to-event end points were analyzed using the Kaplan-Meier method to estimate survival curves and medians; corresponding 95% CI for median estimates were calculated using Brookmeyer-Crowley method.”
> “CI is calculated using Clopper-Pearson method.”
> “Treatment-emergent AEs (TEAEs) were summarized descriptively by category: all AEs, grade ≥3 AEs, treatment-related AEs (TRAEs), AEs leading to study drug reductions or discontinuations, and serious AEs (SAEs).”

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802)

<a id="topic-3.1.2.7.2-4"></a>

###### First-line cohort: censoring rules for progression-free survival

> “Patients who discontinued the study and were lost to follow-up without a known date of progression or death due to any cause on or before the cutoff date were censored at the date of their last available tumor assessment (or, if no tumor assessment was performed after the baseline visit, at the date of first dose of study drug plus 1 day).”

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802)

<a id="topic-3.1.2.7.2-5"></a>

###### HLA-A∗02:01-positive expansion: efficacy-evaluable population and all-enrolled population

> “Response assessments utilized the efficacy evaluable population which includes all patients had ≥3 post-baseline assessments or who discontinued treatment.”
> “PFS and OS assessments utilized the all enrolled Population which include all patients who had ≥1 dose of treatment.”

Source: [McKean et al. (2026a)](https://www.ideayabio.com/sites/default/files/publications/2026-11/ESMO-2026-McKean-OptimUM-01.pdf)

<a id="heading-3.1.2.8"></a>

##### 3.1.2.8 Results

<a id="heading-3.1.2.8.1"></a>

###### 3.1.2.8.1 Participant Disposition

<a id="topic-3.1.2.8.1-1"></a>

###### First-line cohort: discontinuations due to treatment-emergent adverse events

> “TEAEs leading to discontinuation occurred in three patients (6.8%), with each discontinuation attributed to a different AE (1 patient each with cancer fatigue, peripheral edema, and grade 5 AE).”

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802)

<a id="topic-3.1.2.8.1-2"></a>

###### HLA-A∗02:01-positive expansion: discontinuations due to adverse events

> “treatment discontinuations due to AEs occurred in 15 patients (14.9%), 9 of which were considered treatment-related”

Source: [McKean et al. (2026a)](https://www.ideayabio.com/sites/default/files/publications/2026-11/ESMO-2026-McKean-OptimUM-01.pdf)

<a id="topic-3.1.2.8.1-3"></a>

###### First-line and pretreated cohorts, data cutoff of August 22, 2023: duration of treatment and participants continuing treatment

> “With approximately 5.5 months of additional follow-up from the previous data analysis cut-off date (March 8, 2023 to August 22, 2023), now approximately 30% of any-line MUM patients have been on treatment greater than one year and multiple patients with confirmed PRs by RECIST 1.1 have been on treatment greater than 24 months, with the potential for further enhancement on the duration of treatment (DOT) analysis as approximately 20% (13 out of 63 evaluable patients) of any-line MUM patients are continuing on treatment.”
> “Five patients (7%) discontinued treatment with darovasertib and crizotinib combination due to a drug-related adverse event.”

Source: [IDEAYA Biosciences press release, ESMO 2023 phase 2 results (2023)](https://media.ideayabio.com/2023-10-23-IDEAYA-Announces-Top-Line-Phase-2-Results-at-ESMO-2023-of-Darovasertib-and-Crizotinib-Combo-in-MUM,-and-Clinical-Efficacy-Updates-for-Neoadjuvant-UM,-GNAQ-11-Cutaneous-Melanoma,-and-Synthetic-Lethality-Pipeline)

<a id="heading-3.1.2.8.2"></a>

###### 3.1.2.8.2 Baseline Characteristics

<a id="topic-3.1.2.8.2-1"></a>

###### First-line cohort: baseline characteristics of 44 participants

| Characteristic | First-line cohort, N = 44 |
| --- | --- |
| Age, median years (range) | “64.5 (21, 80)” |
| Age less than 65 years, No. (%) | “22 (50.0)” |
| Female, No. (%) | “21 (47.7)” |
| Male, No. (%) | “23 (52.3)” |
| Race White, No. (%) | “41 (93.2%)” |
| Race Asian, No. (%) | “1 (2.3%)” |
| Race other or not reported, No. (%) | “2 (4.5%)” |
| ECOG PS 0, No. (%) | “27 (61.4)” |
| ECOG PS 1, No. (%) | “17 (38.6)” |
| Baseline LDH normal, No. (%) | “29 (65.9)” |
| Baseline LDH above ULN, No. (%) | “14 (31.8)” |
| Baseline LDH more than 2× ULN, No. (%) | “7 (15.9)” |
| Largest metastatic lesion 3.0 cm or less, No. (%) | “24 (54.5)” |
| Largest metastatic lesion 3.1 to 8.0 cm, No. (%) | “15 (34.1)” |
| Largest metastatic lesion 8.1 cm or more, No. (%) | “4 (9.1)” |
| Metastases hepatic only, No. (%) | “23 (52.3)” |
| Metastases extrahepatic only, No. (%) | “2 (4.5)” |
| Metastases hepatic and extrahepatic, No. (%) | “18 (40.9)” |
| HLA-A∗02:01 negative, No. (%) | “30 (68.2)” |
| HLA-A∗02:01 positive, No. (%) | “12 (27.3)” |
| HLA-A∗02:01 unknown, No. (%) | “2 (4.5)” |

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802)

<a id="topic-3.1.2.8.2-2"></a>

###### First-line cohort: high-risk features and HLA testing at enrollment

> “Baseline prognostic features in this patient population revealed that the percentage of patients with the largest metastatic lesion of > 3 cm (>M1a) was 43.2%.”
> “Overall, 27.3% of patients were HLA-A*02:01–positive and 68.2% were HLA-A*02:01–negative; HLA status was unknown for approximately 5% of patients because HLA testing was not routinely performed at the time that some patients were enrolled.”

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802)

<a id="topic-3.1.2.8.2-3"></a>

###### First-line cohort: performance status compared by the sponsor with an earlier registrational study

> “The proportion of patients with ECOG PS 1 in the OptimUM-01 study is approximately two times higher than an earlier published registrational study in mUM.”

Source: [IDEAYA Biosciences press release, first-line OptimUM-01 overall survival at SMR 2025 (2025)](https://media.ideayabio.com/2025-10-20-IDEAYA-Biosciences-Reports-Positive-Median-Overall-Survival-Data-from-Phase-2-Trial-of-the-Darovasertib-and-Crizotinib-Combination-in-First-line-Metastatic-Uveal-Melanoma-at-the-2025-Society-for-Melanoma-Research-Congress)

<a id="topic-3.1.2.8.2-4"></a>

###### HLA-A∗02:01-positive expansion: baseline characteristics of treatment-naive and overall populations

| Characteristic | Treatment-naive, N = 13 | Overall, N = 101 |
| --- | --- | --- |
| Age, median years (range) | “65.0 (21, 81)” | “66.0 (21, 81)” |
| Female, n (%) | “7 (53.8)” | “44 (43.6)” |
| Race White, n (%) | “13 (100.0)” | “95 (94.1)” |
| ECOG PS 0, n (%) | “6 (46.2)” | “66 (65.3)” |
| ECOG PS 1, n (%) | “7 (53.8)” | “35 (34.7)” |
| Baseline LDH at or below ULN, n (%) | “7 (53.8)” | “36 (35.6)” |
| Baseline LDH above ULN and below 2× ULN, n (%) | “4 (30.8)” | “43 (42.6)” |
| Baseline LDH 2× ULN or higher, n (%) | “2 (15.4)” | “22 (21.8)” |
| Metastases hepatic only, n (%) | “8 (61.5)” | “51 (50.5)” |
| Metastases extrahepatic only, n (%) | “2 (15.4)” | “12 (11.9)” |
| Metastases hepatic and extrahepatic, n (%) | “3 (23.1)” | “38 (37.6)” |
| No prior lines of therapy, n (%) | “13 (100)” | “13 (12.9)” |

Source: [McKean et al. (2026a)](https://www.ideayabio.com/sites/default/files/publications/2026-11/ESMO-2026-McKean-OptimUM-01.pdf)

| Prior lines of therapy | Overall, N = 101, n (%) |
| --- | --- |
| One prior line of therapy | “20 (19.8)” |
| Two or more prior lines of therapy | “67 (66.3)” |
| Not recorded, previously treated | “1 (1.0)” |

Source: [McKean et al. (2026a)](https://www.ideayabio.com/sites/default/files/publications/2026-11/ESMO-2026-McKean-OptimUM-01.pdf)

<a id="topic-3.1.2.8.2-5"></a>

###### HLA-A∗02:01-positive expansion: prior systemic therapy, including second-line treatment after tebentafusp

> “Most patients (88/101) had received prior systemic therapy for mUM: 13 patients had no prior systemic therapies , and 15 patients received darova+criz in the second line setting after prior tebentafusp as the first-line therapy”
> “Elevated baseline LDH level was present in 64.4%, with 21.8% of patients with an LDH level that was 2x upper limit of normal or higher”

Source: [McKean et al. (2026a)](https://www.ideayabio.com/sites/default/files/publications/2026-11/ESMO-2026-McKean-OptimUM-01.pdf)

<a id="topic-3.1.2.8.2-6"></a>

###### First-line and pretreated cohorts, per-protocol efficacy population: tumor burden and HLA-A∗02:01 status

> “The PPEP had a large tumor burden: 66% with largest metastatic lesion > 3cm, 64% with hepatic + extrahepatic disease, & 60% with elevated LDH.”
> “HLA-A2*02:01 status (n=51 tested): 63% neg., 37% pos.”

Source: [McKean et al. (2023)](https://www.annalsofoncology.org/article/S0923-7534%2823%2903052-1/fulltext)

<a id="heading-3.1.2.8.3"></a>

###### 3.1.2.8.3 Efficacy Results

<a id="topic-3.1.2.8.3-1"></a>

###### First-line cohort, efficacy-evaluable population of 41 participants: response, duration of response, and disease control

| Outcome | First-line cohort, N = 41 |
| --- | --- |
| Objective response rate, No. (%) | “14 (34.1)” |
| Objective response rate, 95% CI | “20.1 to 50.6” |
| Best overall response CR, No. (%) | “0 (0.0)” |
| Best overall response PR, No. (%) | “14 (34.1)” |
| Best overall response SD, No. (%) | “23 (56.1)” |
| Best overall response PD, No. (%) | “4 (9.8)” |
| Duration of response, median months | “9.0” |
| Duration of response, 95% CI | “3.8 to 12.0” |
| Time to response, median months | “2.0” |
| Disease control rate at 8 weeks, No. (%) | “37 (90.2)” |
| Disease control rate at 8 weeks, 95% CI | “76.9 to 97.3” |
| Disease control rate at 26 weeks, No. (%) | “22 (53.7)” |
| Disease control rate at 26 weeks, 95% CI | “37.4 to 69.3” |

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802)

> “Confirmed objective tumor response as assessed by investigator per RECIST 1.1.”
> “Efficacy-evaluable population includes all patients who received at least one dose of study drug and have at least one postbaseline tumor assessment.”

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802)

<a id="topic-3.1.2.8.3-2"></a>

###### First-line cohort: tumor shrinkage

> “Most patients treated with darovasertib-crizotinib experienced evidence of tumor shrinkage.”

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802)

> “A DCR of 90% (37/41) was also observed, with 85% (35/41) of patients achieving 'any reduction' in target lesions.”

Source: [IDEAYA Biosciences press release, first-line OptimUM-01 overall survival at SMR 2025 (2025)](https://media.ideayabio.com/2025-10-20-IDEAYA-Biosciences-Reports-Positive-Median-Overall-Survival-Data-from-Phase-2-Trial-of-the-Darovasertib-and-Crizotinib-Combination-in-First-line-Metastatic-Uveal-Melanoma-at-the-2025-Society-for-Melanoma-Research-Congress)

<a id="topic-3.1.2.8.3-3"></a>

###### First-line cohort, safety population: progression-free survival and overall survival at a median follow-up of 25 months

> “With a median study follow-up of 25 months (time from first treatment to data extraction), the median PFS was 7.0 months (95% CI, 3.8 to 7.7; Fig 2).”
> “The PFS rates at 6 months and 12 months were 52% and 28%, respectively.”
> “A median OS of 21.1 months (95% CI, 12.5 to 27.1) was observed.”
> “OS was analyzed using the safety population, which is defined as all patients who had at least one dose of study drug.”

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802)

<a id="topic-3.1.2.8.3-4"></a>

###### First-line cohort: progression-free survival and overall survival with confidence intervals as stated in the abstract

> “The median PFS and OS were 7.0 months (95% CI, 5.0 to 8.3) and 21.1 months (95% CI, 11.9 to 20.7), respectively.”

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802)

<a id="topic-3.1.2.8.3-5"></a>

###### First-line cohort: confirmed response by HLA-A∗02:01 status

| Outcome | HLA-A∗02:01 positive, n = 10 | HLA-A∗02:01 negative, n = 29 |
| --- | --- | --- |
| Objective response rate, No. (%) | “3 (30.0)” | “9 (31.0)” |
| Objective response rate, 95% CI | “3.7 to 65.2” | “15.3 to 50.8” |
| Best overall response PR, No. (%) | “3 (30.0)” | “9 (31.0)” |
| Best overall response SD, No. (%) | “7 (70.0)” | “16 (55.2)” |
| Best overall response PD, No. (%) | “0 (0.0)” | “4 (13.8)” |
| Disease control rate, No. (%) | “10 (100.0)” | “25 (86.2)” |
| Disease control rate, 95% CI | “NA” | “68.3 to 96.1” |
| Duration of response, median months | “10.15” | “9.03” |
| Duration of response, 95% CI | “3.75 to NE” | “1.94 to 9.03” |
| Time to response, median months | “3.7” | “1.9” |

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802)

<a id="topic-3.1.2.8.3-6"></a>

###### First-line cohort: response in HLA-A∗02:01-positive participants as stated in the discussion

> “The preliminary results in the subset of HLA-A*02:01–positive treatment-naïve patients with mUM suggest that the observed ORR of 40% with darovasertib-crizotinib, if validated in a larger patient sample, could be especially meaningful in those presenting with bulky liver metastasis or extrahepatic disease where initial tumor shrinkage may be important to relieve associated symptoms or resulting organ dysfunction.”

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802)

<a id="topic-3.1.2.8.3-7"></a>

###### First-line cohort: response by baseline LDH

| Outcome | LDH at or below ULN, n = 28 | LDH above ULN to 2× ULN, n = 7 | LDH above 2× ULN, n = 6 |
| --- | --- | --- | --- |
| Objective response rate, No. (%) | “8 (28.6)” | “2 (28.6)” | “4 (66.7)” |
| Objective response rate, 95% CI | “13.2 to 48.7” | “3.7 to 71.0” | “22.3 to 95.7” |
| Best overall response SD, No. (%) | “17 (60.7)” | “4 (57.1)” | “2 (33.3)” |
| Best overall response PD, No. (%) | “3 (10.7)” | “1 (14.3)” | “0 (0.0)” |
| Disease control rate, No. (%) | “25 (89.3)” | “6 (85.7)” | “6 (100)” |

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802)

<a id="topic-3.1.2.8.3-8"></a>

###### First-line cohort: response by tumor burden (largest metastatic lesion)

| Outcome | 3 cm or less, n = 23 | Above 3 cm to 8 cm, n = 15 | Above 8 cm, n = 3 |
| --- | --- | --- | --- |
| Objective response rate, No. (%) | “9 (39.1)” | “4 (26.7)” | “1 (33.3)” |
| Objective response rate, 95% CI | “19.7 to .61.5” | “7.8 to 55.1” | “0.8 to 90.6” |
| Best overall response SD, No. (%) | “14 (60.9)” | “7 (46.7)” | “2 (66.7)” |
| Best overall response PD, No. (%) | “0 (0.0)” | “4 (26.7)” | “0 (0.0)” |
| Disease control rate, No. (%) | “23 (100.0)” | “11 (73.3)” | “3 (100.0)” |

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802)

> “Outcomes were evaluated across LDH subgroups and baseline tumor burden, and responses were observed in all categories (Appendix Table A5).”

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802)

<a id="topic-3.1.2.8.3-9"></a>

###### First-line cohort: molecular response in circulating cell-free DNA

> “Among the patients with reported GNAQ/11 mutations from tumor tissue (n = 20), plasma was tested and all patients had detectable cfDNA at baseline (Appendix Fig A3).”
> “Among these, 95% (19/20) demonstrated a molecular response with > 50% reduction in detectable cfDNA from baseline.”

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802)

<a id="topic-3.1.2.8.3-10"></a>

###### HLA-A∗02:01-positive expansion: response, progression-free survival, and overall survival in treatment-naive and overall populations

| Outcome | Treatment-naive, N = 13 | Overall, N = 101 |
| --- | --- | --- |
| Objective response rate, n/N (%) | “4/11 (36.4)” | “19/86 (22.1)” |
| Objective response rate, 95% CI | “10.9, 69.2” | “13.9, 32.3” |
| Confirmed best overall response CR, n/N (%) | “0/11 (0.0)” | “0/86 ( 0.0)” |
| Confirmed best overall response SD, n/N (%) | “6/11 (54.5)” | “49/86 (57.0)” |
| Confirmed best overall response PD, n/N (%) | “0/11 (0.0)” | “9/86 (10.5)” |
| Confirmed best overall response not evaluable, n/N (%) | “1/11 (9.1)” | “9/86 (10.5)” |
| Disease control rate, n/N (%) | “10/11 (90.9)” | “69/86 (80.2)” |
| Median progression-free survival, 95% CI | “3.6, 19.6” | “3.7, 6.8” |
| Median overall survival, 95% CI | “8.9, NE” | “9.8, 26.3” |

Source: [McKean et al. (2026a)](https://www.ideayabio.com/sites/default/files/publications/2026-11/ESMO-2026-McKean-OptimUM-01.pdf)

> “The confirmed ORR was 36.4% in treatment-naïve patients and 22.1% in overall population (Table 2)”
> “The median PFS in treatment-naïve and overall population were 7.4 months (95%CI: 3.6-19.6) and 5.4 months (95%CI: 3.7-6.8), respectively (Table 2; Figure 2)”
> “The median OS was 27.1 months (95%CI: 8.9, not evaluable) and 13.4 months (95%CI: 9.8, 26.3) in treatment-naïve and overall populations, respectively (Table 2; Figure 3)”

Source: [McKean et al. (2026a)](https://www.ideayabio.com/sites/default/files/publications/2026-11/ESMO-2026-McKean-OptimUM-01.pdf)

<a id="topic-3.1.2.8.3-11"></a>

###### HLA-A∗02:01-positive expansion: second-line participants after tebentafusp

> “In second-line patients following tebentafusp, the confirmed ORR, median PFS, and median OS was 35.7%, 5.7 months (95%CI: 3.7, not evaluable), and 12.1 months (95%CI: 9.8, not evaluable), respectively”

Source: [McKean et al. (2026a)](https://www.ideayabio.com/sites/default/files/publications/2026-11/ESMO-2026-McKean-OptimUM-01.pdf)

| Outcome | Prior tebentafusp (second line), N = 15 |
| --- | --- |
| Objective response rate, n/N | “(5/14)” |
| Objective response rate, 95% CI | “12.8-64.9” |
| Disease control rate, % | “85.7%” |
| Disease control rate, n/N | “(12/14)” |
| Median duration of response | “5.6 mos” |
| Median progression-free survival, 95% CI | “3.65-NE” |
| Median overall survival, 95% CI | “9.79-NE” |

Source: [IDEAYA Biosciences press release, ESMO 2026 data (2026)](https://media.ideayabio.com/2026-10-19-IDEAYA-Biosciences-and-Servier-Announce-Data-From-Three-Clinical-Trials-at-ESMO-2026-Supporting-the-Potential-of-Darovasertib-to-Become-a-Foundational-New-Therapy-for-Patients-Across-the-Treatment-Journey-of-Uveal-Melanoma)

<a id="topic-3.1.2.8.3-12"></a>

###### HLA-A∗02:01-negative participants of OptimUM-01 as reported for comparison in the HLA-A∗02:01-positive expansion poster

| Outcome | HLA-A∗02:01 negative, treatment-naive, N = 29 | HLA-A∗02:01 negative, overall, N = 61 |
| --- | --- | --- |
| Objective response rate, n/N (%) | “9/29 (31.0)” | “16/61 (26.2)” |
| Objective response rate, 95% CI | “15.3, 50.8” | “15.8, 39.1” |
| Disease control rate, n/N (%) | “25/29 (86.2)” | “53/61 (86.9)” |
| Median progression-free survival, 95% CI | “3.7, 9.2” | “5.0, 7.8” |
| Median overall survival, 95% CI | “12.0, 23.8” | “11.7, 20.7” |

Source: [McKean et al. (2026a)](https://www.ideayabio.com/sites/default/files/publications/2026-11/ESMO-2026-McKean-OptimUM-01.pdf)

> “Efficacy results with darova+criz treatment among HLA-A02:01-positive patients was generally consistent to those for HLA-A02:01-negative patients enrolled in the OptimUM-01 study in both treatment-naïve patients and overall population (Table 3)”

Source: [McKean et al. (2026a)](https://www.ideayabio.com/sites/default/files/publications/2026-11/ESMO-2026-McKean-OptimUM-01.pdf)

<a id="heading-3.1.2.8.4"></a>

###### 3.1.2.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.2.8.5"></a>

###### 3.1.2.8.5 Safety Results

<a id="topic-3.1.2.8.5-1"></a>

###### First-line cohort: dose intensity

> “Mean percent cumulative dose intensity was 84.9% for darovasertib and 80.0% for crizotinib.”

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802)

> “The median dose intensity for darovasertib and crizotinib was 92.6% and 88.0%, respectively”

Source: [McKean et al. (2025)](https://www.ideayabio.com/sites/default/files/publications/2026-11/SMR-2025-McKean-OptimUM-01.pdf)

<a id="topic-3.1.2.8.5-2"></a>

###### First-line cohort: treatment-emergent adverse event summary

| Adverse event | All grades, No. (%) | Grade 3 or higher, No. (%) |
| --- | --- | --- |
| Any AE | “44 (100)” | “23 (52.3)” |
| Serious AE | “9 (20.5)” | “8 (18.2)” |
| AE leading to discontinuation | “3 (6.8)” | “1 (2.3)” |
| AEs related to darovasertib leading to reduction | “3 (6.8)” | “0” |
| AEs related to crizotinib leading to reduction | “4 (9.1)” | “1 (2.3)” |
| Diarrhea | “42 (95.5)” | “1 (2.3)” |
| Nausea | “37 (84.1)” | “0” |
| Edema peripheral | “27 (61.4)” | “0” |
| Vomiting | “23 (52.3)” | “0” |
| Dermatitis acneiform | “20 (45.5)” | “0” |
| Hypoalbuminemia | “19 (43.2)” | “1 (2.3)” |
| Fatigue | “18 (40.9)” | “0” |
| Constipation | “13 (29.5)” | “1 (2.3)” |
| Dizziness | “13 (29.5)” | “1 (2.3)” |
| Decreased appetite | “11 (25.0)” | “0” |
| Alanine aminotransferase increased | “9 (20.5)” | “2 (4.5)” |
| Headache | “9 (20.5)” | “0” |
| Aspartate aminotransferase increased | “8 (18.2)” | “1 (2.3)” |
| Cough | “8 (18.2)” | “0” |
| Dyspnea | “8 (18.2)” | “0” |
| Hypophosphatemia | “8 (18.2)” | “0” |
| Hypotension | “8 (18.2)” | “1 (2.3)” |
| Anemia | “7 (15.9)” | “0” |
| Blood alkaline phosphatase increased | “7 (15.9)” | “0” |
| Dysgeusia | “7 (15.9)” | “0” |
| Blood creatinine increased | “6 (13.6)” | “0” |
| COVID-19 | “6 (13.6)” | “0” |
| Generalized edema | “6 (13.6)” | “1 (2.3)” |
| Hypokalemia | “6 (13.6)” | “2 (4.5)” |
| Pruritus | “6 (13.6)” | “0” |
| Rash maculopapular | “6 (13.6)” | “0” |
| Vision blurred | “6 (13.6)” | “2 (4.5)” |
| Blood lactate dehydrogenase increased | “5 (11.4)” | “0” |
| Cancer fatigue | “5 (11.4)” | “0” |
| Face edema | “5 (11.4)” | “0” |
| Gastroesophageal reflux disease | “5 (11.4)” | “0” |
| Iron deficiency anemia | “5 (11.4)” | “3 (6.8)” |
| Periorbital edema | “5 (11.4)” | “0” |

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802)

> “Other ≥ grade 3 AEs occurring in >5% of patients: pulmonary embolism (9.1%). 3 patients had ≥ grade 3 AEs leading to treatment discontinuation (cancer fatigue, edema peripheral, and sudden death).”

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802)

<a id="topic-3.1.2.8.5-3"></a>

###### First-line cohort: most common adverse events, grade 3 or higher events, serious adverse events, and deaths

> “Overall, all participants experienced at least one AE during the trial. The most common TEAEs (Table 2) and TRAEs (Appendix Table A1) were diarrhea (treatment-emergent: 95.5%; treatment-related: 90.0%), nausea (84.1%; 79.5%), peripheral edema (61.4%; 61.4%), and vomiting (52.3%; 47.7%).”
> “Grade 3 or greater TEAEs were experienced by 52.3% of participants (Table 2). The most common grade 3 or greater AEs were pulmonary embolism (9.1%) and iron deficiency anemia (6.8%). Treatment-emergent SAEs occurred in 20.5% of patients, with the most common being pulmonary embolism (2 patients [4.5%]; Appendix Tables A2 and A3).”
> “Two patients (4.5%) experienced grade 5 AEs, one of which was unrelated to study treatment (extensive liver disease with malignant ascites) and one of which was deemed possibly related to study treatment but was more likely the result of multiple contributing factors in a patient with advanced metastatic disease, such as worsening ascites, fluid imbalance, and electrolyte disturbances.”

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802)

<a id="topic-3.1.2.8.5-4"></a>

###### First-line cohort: most common adverse events as stated in the abstract

> “The most common adverse events (AEs) were diarrhea (95.2%), nausea (84.1%), peripheral edema (61.4%), and vomiting (52.3%).”

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802)

<a id="topic-3.1.2.8.5-5"></a>

###### First-line cohort: dose reductions and dose holds

> “AEs related to darovasertib leading to dose reduction occurred in three patients (6.8%; one patient each with diarrhea, fatigue, and orthostatic hypotension). AEs related to crizotinib leading to dose reduction occurred in four patients (9.1%; two patients with diarrhea, and one each with fatigue and neutropenia). Thirty patients (68.2%) had at least one dose hold, with 21 having their first dose hold due to an AE and the rest for other reasons.”

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802)

<a id="topic-3.1.2.8.5-6"></a>

###### First-line cohort: treatment-related adverse event summary

| Adverse event | All grades, No. (%) | Grade 3 or higher, No. (%) |
| --- | --- | --- |
| Treatment-related AE | “43 (97.7)” | “12 (27.3)” |
| Treatment-related serious AE | “4 (9.1)” | “3 (6.8)” |
| Treatment-related AE leading to discontinuation | “2 (4.5)” | “1 (2.3)” |
| Diarrhea | “40 (90.9)” | “1 (2.3)” |
| Nausea | “35 (79.5)” | “0” |
| Edema peripheral | “27 (61.4)” | “0” |
| Vomiting | “21 (47.7)” | “0” |
| Dermatitis acneiform | “19 (43.2)” | “0” |
| Hypoalbuminemia | “19 (43.2)” | “1 (2.3)” |
| Fatigue | “17 (38.6)” | “0” |
| Dizziness | “12 (27.3)” | “1 (2.3)” |
| Decreased appetite | “8 (18.2)” | “0” |
| Hypotension | “8 (18.2)” | “1 (2.3)” |
| Constipation | “7 (15.9)” | “0” |
| Aspartate aminotransferase increased | “6 (13.6)” | “0” |
| Dysgeusia | “6 (13.6)” | “0” |
| Rash maculopapular | “6 (13.6)” | “0” |
| Alanine aminotransferase increased | “5 (11.4)” | “1 (2.3)” |
| Anemia | “5 (11.4)” | “0” |
| Blood alkaline phosphatase increased | “5 (11.4)” | “0” |
| Face edema | “5 (11.4)” | “0” |
| Generalized edema | “5 (11.4)” | “0” |
| Hypophosphatemia | “5 (11.4)” | “0” |
| Periorbital edema | “5 (11.4)” | “0” |
| Pruritus | “5 (11.4)” | “0” |

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802)

<a id="topic-3.1.2.8.5-7"></a>

###### First-line cohort: treatment-emergent serious adverse events

| Serious adverse event | Overall population, N = 44, No. (%) |
| --- | --- |
| Any serious adverse event | “9 (20.5)” |
| Ascites | “1 (2.3)” |
| Bacteremia | “1 (2.3)” |
| Cancer pain | “1 (2.3)” |
| Cholecystitis | “1 (2.3)” |
| Diarrhea | “1 (2.3)” |
| Fall | “1 (2.3)” |
| Generalized edema | “1 (2.3)” |
| Pulmonary embolism (listed in two rows of the source table) | “1 (2.3)” |
| Pancreatitis acute | “1 (2.3)” |
| Sudden death | “1 (2.3)” |

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802)

<a id="topic-3.1.2.8.5-8"></a>

###### First-line cohort: treatment-related serious adverse events

| Serious adverse event related to study drug | Overall population, N = 44, No. (%) |
| --- | --- |
| Any serious adverse event related to study drug | “4 (9.1)” |
| Diarrhea | “1 (2.3)” |
| Pulmonary embolism | “1 (2.3)” |
| Syncope | “1 (2.3)” |
| Sudden death | “1 (2.%)” |

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802)

<a id="topic-3.1.2.8.5-9"></a>

###### First-line cohort: hypotension, the most common dose-limiting toxicity of darovasertib monotherapy

> “Hypotension, the most common dose-limiting toxicity observed with darovasertib treatment in the prior phase 1 study,33 occurred in eight patients (18.3%) in this study.”
> “In general, hypotension events occurred early during therapy, with most episodes reported within the first few cycles of treatment. Most hypotension events were mild-to-moderate in severity (grade 1-2), nonserious, and resolved within a short period of time without recurrent events. Only one of these events was ≥grade 3, and there were no reported treatment discontinuations related to hypotension. One patient experienced syncope in association with hypotension early in treatment; this event was resolved shortly thereafter.”

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802)

<a id="topic-3.1.2.8.5-10"></a>

###### First-line cohort: overlapping toxicities of the two agents

> “Therefore, the safety profile was consistent with the known safety profile of the individual agents, although there is some risk of exacerbating some overlapping AEs, such as gastrointestinal AEs, with the combination.”
> “There were no new safety signals identified.”

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802)

<a id="topic-3.1.2.8.5-11"></a>

###### HLA-A∗02:01-positive expansion, overall population: treatment-related adverse events

| Adverse event | Overall, N = 101, n (%) |
| --- | --- |
| Related adverse event | “101 (100)” |
| Related serious adverse event | “12 (11.9)” |
| Related grade 3 or higher adverse event | “38 (37.6)” |
| Related adverse event leading to discontinuation | “9 (8.9)” |
| Related adverse events leading to reduction | “28 (27.7)” |
| Diarrhea | “83 ( 82.2)” |
| Nausea | “77 ( 76.2)” |
| Edema peripheral | “71 ( 70.3)” |
| Vomiting | “58 ( 57.4)” |
| Fatigue | “55 ( 54.5)” |
| Dizziness | “38 ( 37.6)” |
| Dermatitis acneiform | “35 ( 34.7)” |
| Hypotension | “33 ( 32.7)” |

Source: [McKean et al. (2026a)](https://www.ideayabio.com/sites/default/files/publications/2026-11/ESMO-2026-McKean-OptimUM-01.pdf)

> “The most common treatment-related adverse events (TRAEs) were diarrhea (82%), nausea (76%), peripheral edema (70%), and vomiting (57%)(Table 4)”
> “Grade >3 TRAEs included hypotension (5.9%), syncope (5.9%), and pulmonary embolism (5.0%)”

Source: [McKean et al. (2026a)](https://www.ideayabio.com/sites/default/files/publications/2026-11/ESMO-2026-McKean-OptimUM-01.pdf)

<a id="topic-3.1.2.8.5-12"></a>

###### First-line and pretreated cohorts at the expansion dose, safety population: drug-related adverse events

> “In the SP, the most common drug-related adverse events (AEs) (>30%) were diarrhea, nausea, edema, fatigue, hypotension & rash. AEs were largely Grade 1-2. Related Serious AEs were seen in 6 (9%) pts and AEs leading to discontinuation in 4 (6%) pts.”

Source: [McKean et al. (2023)](https://www.annalsofoncology.org/article/S0923-7534%2823%2903052-1/fulltext)

<a id="topic-3.1.2.8.5-13"></a>

###### First-line and pretreated cohorts, 68 participants: drug-related adverse events and serious adverse events

> “The darovasertib and crizotinib combination continued to demonstrate an overall manageable adverse event profile in MUM patients (n=68), with a low rate (10%) of drug-related serious adverse events (SAEs) and limited Grade 4 and Grade 5 SAEs and discontinuations.”
> “31% of patients reported at least one Grade 3 AE; no patients observed a Grade 4 AE; and one patient observed a Grade 5 AE.”

Source: [IDEAYA Biosciences press release, ESMO 2023 phase 2 results (2023)](https://media.ideayabio.com/2023-10-23-IDEAYA-Announces-Top-Line-Phase-2-Results-at-ESMO-2023-of-Darovasertib-and-Crizotinib-Combo-in-MUM,-and-Clinical-Efficacy-Updates-for-Neoadjuvant-UM,-GNAQ-11-Cutaneous-Melanoma,-and-Synthetic-Lethality-Pipeline)

<a id="topic-3.1.2.8.5-14"></a>

###### Pretreated cohort, 22 participants: drug-related adverse events

> “The darovasertib and crizotinib combination therapy has a manageable side effect profile in MUM patients (n=22), with a low rate of drug-related serious adverse events (SAE's); predominantly Grade 1 or 2 drug-related adverse events.”
> “Eighteen (18) patients experienced a drug-related AE, of which six (6) patients observed Grade 3, and no patients observed Grade 4 or Grade 5.”

Source: [IDEAYA Biosciences press release, phase 2 expansion dose data in pretreated metastatic uveal melanoma (2021)](https://media.ideayabio.com/2021-12-07-IDEAYA-Reports-Clinical-Data-from-Phase-2-Expansion-Dose-of-Darovasertib-and-Crizotinib-Synthetic-Lethal-Combination-in-Heavily-Pre-Treated-Metastatic-Uveal-Melanoma)

<a id="heading-3.1.2.9"></a>

##### 3.1.2.9 Study Limitations

<a id="topic-3.1.2.9-1"></a>

###### Summary

The OptimUM-01 first-line cohort is an open-label, single-arm, nonrandomized expansion of 44 participants, of whom 41 were efficacy-evaluable; the authors describe the data as hypothesis-generating. No formal hypothesis testing was prespecified, and all results were summarized descriptively. Response was assessed by the investigator per RECIST version 1.1. The efficacy-evaluable population required at least one post-baseline tumor assessment, which excluded two participants who discontinued before assessment (one for sudden death) and one ongoing participant; PFS and OS were measured from the first day of treatment in the safety population, and OS is an exploratory end point. The authors state that PFS and OS results are preliminary and that the proportion censored and the medians will change with longer follow-up. Disease control was defined as stable disease lasting at least 8 weeks, where OptimUM-02 required at least 12 weeks. The HLA-A∗02:01 subgroups comprise 29 HLA-A∗02:01-negative and 10 HLA-A∗02:01-positive evaluable participants, and HLA status was unknown for about 5% because testing was not routinely performed at enrollment. Molecular response could be assessed in only the 20 participants with driver mutations reported from tumor tissue. The study reports no quality-of-life or patient-reported outcome results; its end points were safety, ORR, duration of response, disease control rate, PFS, and OS. Comparisons with historical data sets carry, in the authors' words, “the necessary caveats and limitations of cross-study comparisons”.

In the HLA-A∗02:01-positive expansion, response was assessed in an efficacy-evaluable population of participants with at least 3 post-baseline assessments or who discontinued treatment, giving denominators of 11 of 13 treatment-naive and 86 of 101 overall participants. IDEAYA's earlier phase 2 results for 68 participants receiving the combination (data cutoff August 22, 2023) were preliminary and based on investigator review from an unlocked database.

Within the first-line cohort publication, the 95% CIs for median PFS (3.8 to 7.7 months in the results; 5.0 to 8.3 months in the abstract) and median OS (12.5 to 27.1 months; 11.9 to 20.7 months) differ, as do the ORR in HLA-A∗02:01-positive participants (30.0%, 3 of 10, in the subgroup table; 40% in the discussion), the incidence of diarrhea (95.5%; 95.2%), and the incidence of hypotension (18.3%; 18.2%).

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802); [ClinicalTrials.gov NCT03947385](https://clinicaltrials.gov/study/NCT03947385); [McKean et al. (2026a)](https://www.ideayabio.com/sites/default/files/publications/2026-11/ESMO-2026-McKean-OptimUM-01.pdf); [Orloff et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO.2026.44.17_suppl.LBA9503); [IDEAYA Biosciences press release, ESMO 2023 phase 2 results (2023)](https://media.ideayabio.com/2023-10-23-IDEAYA-Announces-Top-Line-Phase-2-Results-at-ESMO-2023-of-Darovasertib-and-Crizotinib-Combo-in-MUM,-and-Clinical-Efficacy-Updates-for-Neoadjuvant-UM,-GNAQ-11-Cutaneous-Melanoma,-and-Synthetic-Lethality-Pipeline)

<a id="topic-3.1.2.9-2"></a>

###### First-line cohort: open-label, single-arm design and immature survival data

> “Limitations include that this is an open-label, single-arm study, so the data presented should be considered hypothesis-generating. In addition, the results for PFS and OS analysis are considered preliminary; the proportion of patients censored and median OS and PFS results will continue to mature with longer follow-up.”

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802)

<a id="topic-3.1.2.9-3"></a>

###### First-line cohort: cross-study comparisons with historical data

> “With the necessary caveats and limitations of cross-study comparisons, the PFS and OS results of this study are encouraging relative to the outcomes reported in relevant historical data sets for patients with mUM.”

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802)

<a id="topic-3.1.2.9-4"></a>

###### First-line cohort: molecular response limited to participants with known tumor driver mutations

> “Patients without available information about driver mutations from tumor tissue were unable to be assessed for molecular response.”

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802)

<a id="topic-3.1.2.9-5"></a>

###### Efficacy by HLA-A2 serotype from a preliminary analysis of an unlocked database as of August 22, 2023

> “The reported efficacy data by HLA-A2 serotype was based on a preliminary analysis of an unlocked database as of August 22, 2023 by investigator review and RECIST 1.1.”

Source: [IDEAYA Biosciences press release, ESMO 2023 phase 2 results (2023)](https://media.ideayabio.com/2023-10-23-IDEAYA-Announces-Top-Line-Phase-2-Results-at-ESMO-2023-of-Darovasertib-and-Crizotinib-Combo-in-MUM,-and-Clinical-Efficacy-Updates-for-Neoadjuvant-UM,-GNAQ-11-Cutaneous-Melanoma,-and-Synthetic-Lethality-Pipeline)

<a id="heading-3.1.3"></a>

#### 3.1.3 CLXS196X2101

<a id="heading-3.1.3.1"></a>

##### 3.1.3.1 Objective

<a id="topic-3.1.3.1-1"></a>

###### Primary, secondary, and exploratory objectives of single-agent LXS196

> “In this phase I trial, we aimed to evaluate the safety, preliminary efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of LXS196, and to determine the MTD and/or recommended dose for expansion (RDE) of LXS196 as a single agent in patients with MUM.”
> “The primary objectives were to characterise the safety and tolerability and identify the MTD and/or RDE of LXS196 as a single agent in patients with MUM.”
> “Secondary objectives included investigation of the preliminary antitumour activity of LXS196 and evaluation of the PK and PD of LXS196.”
> “Exploratory objectives included assessment of mutations in cancer driver genes by transcriptome and targeted DNA sequencing of baseline tumour biopsies.”

Source: [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/)

<a id="topic-3.1.3.1-2"></a>

###### Registry title and purpose, including a combination part with HDM201

> “A Phase I, Multi-center, Open-label, Study of LXS196, an Oral Protein Kinase C Inhibitor, in Patients With Metastatic Uveal Melanoma”
> “This study was to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary anti-tumor activity of LXS196 as a single agent and in combination with HDM201 in patients with metastatic uveal melanoma.”

Source: [ClinicalTrials.gov NCT02601378](https://clinicaltrials.gov/study/NCT02601378)

<a id="heading-3.1.3.2"></a>

##### 3.1.3.2 Location and Study Date

<a id="topic-3.1.3.2-1"></a>

###### Novartis-sponsored multicenter study initiated on 1 February 2016

> “This was a phase I, first-in human, multicentre, open-label study (NCT02601378), designed and sponsored by Novartis Pharmaceuticals Corporation and initiated on 1 February 2016.”

Source: [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/)

<a id="topic-3.1.3.2-2"></a>

###### Registry protocol number and study dates

| Study characteristic | Quoted record |
| --- | --- |
| Other study ID number | “CLXS196X2101” |
| Study start (actual) | “2016-02-01” |
| Primary completion (actual) | “2022-01-07” |
| Study completion (actual) | “2022-01-07” |

Source: [ClinicalTrials.gov NCT02601378](https://clinicaltrials.gov/study/NCT02601378)

<a id="topic-3.1.3.2-3"></a>

###### Registry study sites in six countries

| Country | Quoted location | Quoted site |
| --- | --- | --- |
| United States | “New York, New York, United States, 10032” | “Columbia University Medical Center” |
| Australia | “Westmead, New South Wales, Australia, 2145” | “Novartis Investigative Site” |
| France | “Paris, France, 75231” | “Novartis Investigative Site” |
| Netherlands | “Leiden, Netherlands, 2300 RC” | “Novartis Investigative Site” |
| Norway | “Oslo, Norway, 0379” | “Novartis Investigative Site” |
| Spain | “Madrid, Spain, 28050” | “Novartis Investigative Site” |

Source: [ClinicalTrials.gov NCT02601378](https://clinicaltrials.gov/study/NCT02601378)

<a id="heading-3.1.3.3"></a>

##### 3.1.3.3 Study Design

<a id="topic-3.1.3.3-1"></a>

###### Dose escalation guided by a Bayesian logistic regression model, followed by expansion at the recommended dose

> “Dose escalation was guided by safety, PK data and a two-parameter Bayesian Logistic Regression Model (BLRM) [21] employing escalation with overdose control (EWOC) criteria [22].”
> “Upon determination of the MTD/RDE, the expansion part of the study was opened to further evaluate the safety, tolerability, PK and PD of LXS196 at the RDE in patients with MUM.”

Source: [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/)

<a id="topic-3.1.3.3-2"></a>

###### Once-daily schedule followed by a twice-daily schedule

> “Patients were initially treated on a QD schedule (100–1000 mg QD); however, due to toxicities reported at doses ≥500 mg QD, a BID schedule was then tested (200–400 mg BID).”
> “Following determination of the MTD in the QD dosing schedule, a BID schedule was introduced to explore whether alternative dosing may lead to better tolerability of LXS196.”

Source: [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/)

<a id="topic-3.1.3.3-3"></a>

###### Ethics and Good Clinical Practice

> “The study was conducted according to the principles of the Declaration of Helsinki and performed in compliance with Good Clinical Practice.”

Source: [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/)

<a id="topic-3.1.3.3-4"></a>

###### Registry design and status: nonrandomized, open-label, single group; combination part terminated

| Study characteristic | Quoted record |
| --- | --- |
| Primary purpose | “Treatment” |
| Allocation | “Non-Randomized” |
| Interventional model | “Single Group Assignment” |
| Masking | “None (Open Label)” |

Source: [ClinicalTrials.gov NCT02601378](https://clinicaltrials.gov/study/NCT02601378)

> “The combination part of the study was terminated early due to business reasons”

Source: [ClinicalTrials.gov NCT02601378](https://clinicaltrials.gov/study/NCT02601378)

<a id="heading-3.1.3.4"></a>

##### 3.1.3.4 Eligibility Criteria

<a id="topic-3.1.3.4-1"></a>

###### Adults with biopsy-proven progressive and measurable metastatic disease

> “All patients were aged ≥18 years old and had biopsy-proven MUM with progressive and measurable disease.”
> “Patients were required to have an Eastern Cooperative Oncology Group (ECOG) performance status of ≤1 and requested to provide a tumour biopsy at baseline (pre-treatment) and on treatment at day 15 of cycle 1 (C1D15).”

Source: [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/)

<a id="topic-3.1.3.4-2"></a>

###### Treatment-naive or pretreated disease, with no limit on prior lines

> “Patients were either treatment naïve or their disease had progressed (radiologically or clinically) on their most recent therapy. There was no eligibility limit to the number of prior lines of therapy, including PKC inhibitors other than LXS196.”

Source: [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/)

<a id="topic-3.1.3.4-3"></a>

###### Exclusion of cardiac disease, interacting medications, and impaired gastrointestinal function

> “Exclusion criteria included impaired cardiac function or clinically significant cardiac diseases, receipt of concomitant medications known to be strong inducers or inhibitors of cytochrome P450 3A4/5 or known for QT prolongation risk, and impaired GI function that could interfere with absorption of LXS196.”

Source: [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/)

<a id="topic-3.1.3.4-4"></a>

###### Registry: measurable disease definition, central nervous system metastases, and laboratory exclusions

> “Measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as > 20 mm with conventional techniques or as >10 mm with CT scan.”
> “Symptomatic or untreated CNS metastases or spinal cord compression. Brain metastasis must be stable with verification by imaging .”
> “AST or ALT > 3 times ULN, AST or ALT > 5 times ULN for patients with liver metastases.”
> “Total bilirubin > 1.5 x ULN, except for patients with Gilbert's syndrome who are excluded if total bilirubin > 3.0 x ULN or direct bilirubin > 1.5 x ULN.”

Source: [ClinicalTrials.gov NCT02601378](https://clinicaltrials.gov/study/NCT02601378)

<a id="heading-3.1.3.5"></a>

##### 3.1.3.5 Treatment

<a id="topic-3.1.3.5-1"></a>

###### Oral LXS196 once or twice daily in 28-day cycles

> “During dose escalation, patients received oral LXS196 either once daily (QD; 100–1000 mg) or twice daily (BID; 200–400 mg) in 28-day cycles until disease progression, intolerable toxicity or withdrawal of consent (Supplementary Fig. 1).”
> “Dosing was omitted on the second day of the first cycle (C1D2) to allow for longer post-dose sampling in order to better characterise PK.”
> “LXS196 was given on an empty stomach, at least 1 h before or 2 h after a meal.”
> “Patients enroled in the expansion part (n = 12) received LXS196 at the RDE.”

Source: [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/)

<a id="topic-3.1.3.5-2"></a>

###### Dose adjustments and management of hypotension per protocol

> “For patients who did not tolerate their assigned dosing schedule due to a treatment-related AE, dose adjustments were permitted to allow the patient to continue study treatment once the AE had resolved to ≤grade 1.”

Source: [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/)

<a id="heading-3.1.3.6"></a>

##### 3.1.3.6 Study Outcomes

<a id="heading-3.1.3.6.1"></a>

###### 3.1.3.6.1 Rationale for Using Dose-limiting Toxicity as the Primary Endpoint

<a id="topic-3.1.3.6.1-1"></a>

###### Dose-limiting toxicity period and evaluability for the dose-escalation model

> “The DLT period lasted 28 days after the first dose of LXS196.”
> “A patient was evaluable for the BLRM if the patient took at least 75% of the planned doses during the DLT period or had a DLT.”

Source: [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/)

<a id="topic-3.1.3.6.1-2"></a>

###### Nonclinical findings that anticipated hypotension and gastrointestinal toxicity

> “Data from non-clinical single-dose and 4-week repeated dose toxicology studies in dog, suggested that a decrease in systolic blood pressure may be a potential toxicity observed in patients treated with LXS196. The 4-week toxicology study also identified the GI tract as a potential target of LXS196.”

Source: [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/)

<a id="topic-3.1.3.6.1-3"></a>

###### Safety assessments and adverse event grading

> “Routine safety assessments, including laboratory assessments, physical examinations, vital signs and electrocardiograms (ECGs), were conducted at regular intervals throughout the study and more frequently as needed following patient assessment by the treating physician.”
> “Adverse events (AEs) were assessed continuously according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v4.03.”

Source: [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/)

<a id="topic-3.1.3.6.1-4"></a>

###### Tumor response by local RECIST v1.1 assessment

> “Tumour response was assessed locally by computed tomography (CT) and/or magnetic resonance imaging (MRI) of the chest, abdomen and pelvis, according to Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 at baseline, on C3D1 and every two cycles thereafter until cycle 11. After 11 cycles of treatment, response was evaluated every three cycles until the end of treatment.”

Source: [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/)

<a id="topic-3.1.3.6.1-5"></a>

###### Registry primary outcomes

| Outcome | Quoted measure | Quoted time frame |
| --- | --- | --- |
| Dose-limiting toxicities | “Incidence of dose limiting toxicities (DLTs) (Dose escalation only)” | “Cycle 1 in dose escalation” |
| Adverse events | “Incidence and severity of adverse events and serious adverse events, including changes in laboratory parameters, vital signs and ECGs graded as per NCI CTCAE version 4.03 (All patients)” | “Continuously throughout the study until 30 days after treatment discontinuation” |
| Dose modifications | “Dose interruptions, reductions and dose intensity” | “Continuously throughout the study until 30 days after treatment discontinuation” |

Source: [ClinicalTrials.gov NCT02601378](https://clinicaltrials.gov/study/NCT02601378)

<a id="topic-3.1.3.6.1-6"></a>

###### Registry secondary outcomes of efficacy and pharmacodynamics

| Outcome | Quoted measure | Quoted time frame |
| --- | --- | --- |
| Objective response rate | “Overall response rate (ORR) per RECIST version 1.1 criteria” | “From baseline, every 2 cycles until cycle 11, then every 3 cycles afterwards until disease progression or withdrawal of consent up to 12 months” |
| Progression-free survival | “Progression free survival (PFS) per RECIST version 1.1 criteria” | “From baseline, every 2 cycles until cycle 11, then every 3 cycles afterwards until disease progression or withdrawal of consent up to 12 months” |
| Pharmacodynamics | “Modulation of signaling molecules downstream of PKC” | “Baseline and Cycle 1 Day 15” |

Source: [ClinicalTrials.gov NCT02601378](https://clinicaltrials.gov/study/NCT02601378)

<a id="heading-3.1.3.7"></a>

##### 3.1.3.7 Statistical Analysis Description

<a id="heading-3.1.3.7.1"></a>

###### 3.1.3.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.3.7.1-1"></a>

###### Single-agent part: 68 participants treated, 56 in dose escalation and 12 in expansion

> “A total of 68 patients with MUM were treated with LXS196 in this first-in-human study: 56 in the dose escalation part and 12 in dose expansion (Supplementary Fig. 1).”
> “Patients enroled in dose escalation received doses ranging from 100–1000 mg QD (n = 38) and 200–400 mg BID (n = 18) until the RDE was established.”
> “Patients received LXS196 doses ranging from 100–1000 mg once daily (QD; n = 38) and 200–400 mg twice daily (BID; n = 30).”

Source: [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/)

<a id="topic-3.1.3.7.1-2"></a>

###### Sample size selected for the dose-escalation model, without a formal calculation

> “No hypothesis testing was planned in this study, and therefore, no formal sample size calculation was needed. The sample size was selected to ensure the BLRM had adequate operating characteristics when selecting the MTD/RDE.”

Source: [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/)

<a id="topic-3.1.3.7.1-3"></a>

###### Registry: planned enrollment of the single-agent and HDM201 combination parts and actual enrollment

> “About 68 patients will be enrolled in dose escalation and expansion”
> “about 44 patients to be enrolled in dose escalation and expansion”

Source: [ClinicalTrials.gov NCT02601378](https://clinicaltrials.gov/study/NCT02601378)

| Study characteristic | Quoted record |
| --- | --- |
| Enrollment (actual), single-agent and HDM201 combination parts | “107” |

Source: [ClinicalTrials.gov NCT02601378](https://clinicaltrials.gov/study/NCT02601378)

<a id="heading-3.1.3.7.2"></a>

###### 3.1.3.7.2 Description of Analysis Sets

<a id="topic-3.1.3.7.2-1"></a>

###### Population evaluable for maximum tolerated dose determination

> “Fifty-five patients were evaluable for MTD/RDE determination, with one patient excluded from the DLT analysis due lack of sufficient exposure to study treatment during cycle 1.”

Source: [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/)

<a id="topic-3.1.3.7.2-2"></a>

###### Response population including participants without post-baseline assessment

> “Two patients did not have post-baseline tumour assessments due to clinical disease progression before the first scheduled assessment. Hence, the BOR is unknown per RECIST 1.1, however, they are included in the denominator for ORR and DCR calculations.”
> “Estimate [95% CI] for ORR and DCR were obtained using Clopper and Pearson’s method.”

Source: [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/)

<a id="topic-3.1.3.7.2-3"></a>

###### Descriptive statistics and Kaplan-Meier estimation

> “Data are presented using descriptive statistics and visualisations. Continuous variables are described with the mean and range. Categorical variables are described using counts and percentages. PFS is described using the Kaplan–Meier (KM) method.”

Source: [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/)

<a id="topic-3.1.3.7.2-4"></a>

###### Pharmacodynamic analysis restricted to the once-daily schedule

> “PD analysis was not performed on tumour samples from patients who received LXS196 on a BID schedule.”

Source: [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/)

<a id="heading-3.1.3.8"></a>

##### 3.1.3.8 Results

<a id="heading-3.1.3.8.1"></a>

###### 3.1.3.8.1 Participant Disposition

<a id="topic-3.1.3.8.1-1"></a>

###### Final data cutoff of 7 January 2022: discontinuation in the once-daily schedule

> “At the final data cut-off date (7 January 2022), all patients in the QD schedule had discontinued treatment due to disease progression.”

Source: [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/)

<a id="topic-3.1.3.8.1-2"></a>

###### Final data cutoff of 7 January 2022: duration of exposure

> “As of the final data cut-off date (7 January 2022), a total of 68 patients had been treated with LXS196 and the median duration of exposure was 3.71 months (range: 1.81–15.28) and 4.6 months (range: 0.33–58.32) for patients in the QD and BID regimens, respectively.”

Source: [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/)

<a id="topic-3.1.3.8.1-3"></a>

###### Single discontinuation due to an adverse event

> “The only AE leading to discontinuation of LXS196 was an SAE of grade 3/4 hepatic failure in a patient treated in the BID schedule with known liver metastases and CTCAE grade 2 transaminases at study entry. The event was suspected to be related to underlying disease progression but was not confirmed by radiological assessment.”

Source: [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/)

<a id="heading-3.1.3.8.2"></a>

###### 3.1.3.8.2 Baseline Characteristics

<a id="topic-3.1.3.8.2-1"></a>

###### Baseline characteristics by schedule and at the recommended dose for expansion

| Characteristic | All QD, n = 38 | All BID, n = 30 | 300 mg BID (RDE), n = 18 | All patients, N = 68 |
| --- | --- | --- | --- | --- |
| Median age, years (range) | “55 (26–76)” | “57 (33–78)” | “56.5 (38–76)” | “56 (26–78)” |
| Male, n (%) | “22 (57.9)” | “14 (46.7)” | “7 (38.9)” | “36 (52.9)” |
| Female, n (%) | “16 (42.1)” | “16 (53.3)” | “11 (61.1)” | “32 (47.1)” |
| ECOG performance status 0, n (%) | “37 (97.4)” | “25 (83.3)” | “14 (77.8)” | “62 (91.2)” |
| ECOG performance status 1, n (%) | “1 (2.6)” | “5 (16.7)” | “4 (22.2)” | “6 (8.8)” |
| Lactate dehydrogenase above ULN, n (%) | “23 (60.5)” | “15 (50.0)” | “8 (44.4)” | “38 (55.9)” |
| No prior systemic therapy, n (%) | “3 (7.9)” | “6 (20.0)” | “6 (33.3)” | “9 (13.2)” |
| One prior systemic therapy, n (%) | “19 (50.0)” | “18 (60.0)” | “9 (50.0)” | “37 (54.4)” |
| Two prior systemic therapies, n (%) | “12 (31.6)” | “2 (6.7)” | “2 (11.1)” | “14 (20.6)” |
| More than two prior systemic therapies, n (%) | “4 (10.5)” | “4 (13.3)” | “1 (5.6)” | “8 (11.8)” |
| Any prior immunotherapeutic agent, n (%) | “22 (57.9)” | “14 (46.7)” | “4 (22.2)” | “36 (52.9)” |
| Prior pembrolizumab, n (%) | “11 (28.9)” | “10 (33.3)” | “4 (22.2)” | “21 (30.9)” |
| Liver-only metastases, n (%) | “13 (34.2)” | “14 (46.7)” | “9 (50.0)” | “27 (39.7)” |
| Liver and other metastases, n (%) | “20 (52.6)” | “13 (43.3)” | “7 (38.9)” | “33 (48.5)” |
| Maximum target lesion diameter, median mm (range) | “39 (11–126)” | “35.5 (11–201)” | “40 (11–201)” | “36 (11–201)” |

Source: [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/)

<a id="topic-3.1.3.8.2-2"></a>

###### Demographics, metastatic sites, and prior therapy

> “The median age was 56.0 years, 36 (52.9%) were male, and most (n = 62; 91.2%) had a performance status of 0. The majority of patients (n = 60; 88.2%) had liver metastases, 27 of whom (14 in the BID schedule and 13 in the QD schedule) had only liver metastases and no other sites of disease at study entry.”
> “Other reported metastatic sites with an incidence of at least 10% included lung (n = 18, 26.5%), bone (n = 13, 19.1%), lymph node (n = 8, 11.8%) and skin (n = 7, 10.3%).”
> “Overall, 59 patients (86.8%) had received prior systemic therapy; the majority having received either one (n = 37, 54.4%) or two prior regimens (n = 14, 20.6%).”
> “The majority of patients (n = 31, 45.6%) had PD as the best overall response (BOR) to their last prior therapy and in these patients, the median time from initiation to discontinuation of last prior therapy was 63 days (range: 14–515).”
> “No patients had received prior tebentafusp.”

Source: [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/)

<a id="topic-3.1.3.8.2-3"></a>

###### GNAQ, GNA11, and BAP1 mutations in baseline tumor biopsies

> “Mutations in the GNAQ and GNA11 genes are tabulated (Supplementary Table 5A); of the 48 patients assessed, 28 were mutant in GNA11 (of which 22 had allele Q209L and 6 had R183C), 16 were mutant in GNAQ (of which 13 had allele Q209P, two Q209L, and one R183Q), and 4 were not called mutant in either gene as the allele fraction was below the limit of detection.”
> “BAP1 mutations resulting in a protein coding change were detected in 44% (21/48) of patients (Supplementary Table 5B).”

Source: [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/)

<a id="heading-3.1.3.8.3"></a>

###### 3.1.3.8.3 Efficacy Results

<a id="topic-3.1.3.8.3-1"></a>

###### Best overall response and progression-free survival by schedule and at the recommended dose for expansion

| Outcome | All QD, n = 38 | All BID, n = 30 | 300 mg BID (RDE), n = 18 | All patients, N = 68 |
| --- | --- | --- | --- | --- |
| Complete response, n (%) | “0” | “1 (3.3)” | “0” | “1 (1.5)” |
| Partial response, n (%) | “2 (5.3)” | “3 (10.0)” | “2 (11.1)” | “5 (7.4)” |
| Stable disease, n (%) | “27 (71.1)” | “18 (60.0)” | “12 (66.7)” | “45 (66.2)” |
| Progressive disease, n (%) | “9 (23.7)” | “6 (20.0)” | “3 (16.7)” | “15 (22.1)” |
| Objective response rate, 95% CI | “[0.6–17.7]” | “[3.8–30.7]” | “[1.4–34.7]” | “[3.3–18.2]” |
| Disease control rate, n (%) | “29 (76.3)” | “22 (73.3)” | “14 (77.8)” | “51 (75.0)” |
| Disease control rate, 95% CI | “[59.8–88.6]” | “[54.1–87.7]” | “[52.4–93.6]” | “[63–84.7]” |
| Median progression-free survival, months (95% CI) | “3.5 (3.5–5.4)” | “4.1 (3.5–7.2)” | “3.7 (2.1–5.4)” | “3.6 (3.5–5.4)” |
| Progression-free survival rate at 4 months, % (95% CI) | “36.8 (22.0–51.8)” | “50.0 (31.3–66.1)” | “44.4 (21.6–65.1)” | “42.6 (30.8–54.0)” |
| Progression-free survival rate at 6 months, % (95% CI) | “26.3 (13.7–40.8)” | “33.3 (17.5–50.0)” | “27.8 (10.1–48.9)” | “29.4 (19.1–29.2)” |
| Progression-free survival rate at 12 months, % (95% CI) | “0.0 (NE–NE)” | “26.7 (12.6–43.0)” | “22.2 (6.9–42.9)” | “11.8 (5.5–20.6)” |

Source: [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/)

<a id="topic-3.1.3.8.3-2"></a>

###### All participants: response, duration of response, and duration of stable disease

> “Clinical activity was observed in 6/66 (9.1%) evaluable patients achieving response (CR/PR), with a median duration of response of 10.15 months (range: 2.99–41.95); 45/66 had stable disease (SD) per RECIST v1.1.”
> “The median duration of response for all patients with a RECIST response (n = 6) was 10 months (2.99–41.95) and median duration of SD (n = 45) was 5.32 months (2.07–30.23).”

Source: [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/)

<a id="topic-3.1.3.8.3-3"></a>

###### Twice-daily schedule and the recommended dose for expansion of 300 mg twice daily: response

> “The ORR in the BID schedule was 13.3% (95% CI: 3.8–30.7) and the disease control rate (DCR) was 73.3% (95% CI: 54.1–87.7) (Table 3).”
> “Of the 18 evaluable patients treated at the RDE of 300 mg BID, 2 (11.1%) had a BOR of PR and 12 (66.7%) had SD (including 3 patients with >30% tumour reduction/unconfirmed PR).”
> “The ORR at the RDE was 11.1% (95% CI: 1.4–34.7) and the DCR was 77.8% (95% CI: 52.4–93.6) (Fig. 3).”

Source: [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/)

<a id="topic-3.1.3.8.3-4"></a>

###### Progression-free survival in all participants, the twice-daily schedule, and at the recommended dose for expansion

> “No patients were censored and 100% of PFS events were reported as of the data cut-off date. Of the 68 events, 66 had disease progression and 2 patients had died. The estimated median PFS was 3.6 months (95% CI: 3.5–5.4) and the estimated PFS rate at 6 months by the KM method was 29.4% (95% CI: 19.1–40.4).”
> “In the BID schedule, the estimated median PFS was 4.1 months (95% CI: 3.5–7.2) and the estimated PFS rate at 6 months by the KM method was 33.3% (95% CI: 17.5–50).”
> “At the RDE of 300 mg BID, the estimated median PFS was 3.7 months (95% CI: 2.1–5.4) and the estimated PFS rate at 6 months by the KM method was 27.8% (95% CI: 10.1–48.9) (Table 3).”

Source: [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/)

<a id="topic-3.1.3.8.3-5"></a>

###### Response by GNAQ or GNA11 mutation status

> “No association of GNAQ/GNA11 mutation status with patient response was observed (Fig. 3).”

Source: [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/)

<a id="topic-3.1.3.8.3-6"></a>

###### Comparison by the authors with the first-generation PKC inhibitor AEB071

> “Regarding efficacy, across all doses tested the ORR was 8.8% with LXS196 versus 3% with AEB071, and 67% of patients had SD as their best response with LXS196 versus 50% with AEB071 (median duration of SD: 5.32 versus 3.75 months, respectively). The estimated median PFS was similar at 3.6 months (95% CI: 3.5–5.4) with LXS196 versus 3.5 months (95% CI: 2.5–3.6) with AEB071.”

Source: [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/)

<a id="topic-3.1.3.8.3-7"></a>

###### Complete response at month 31 reported by the sponsor

> “Confirmed Complete Response observed at month 31 in one patient previously reported with confirmed Partial Response in the ongoing IDE196 monotherapy clinical trial conducted by Novartis (ClinicalTrials.gov Identifier: NCT02601378)”

Source: [IDEAYA Biosciences press release, End-of-Phase 1 meeting with FDA (2019)](https://media.ideayabio.com/2019-10-31-IDEAYA-Biosciences-Reports-End-of-Phase-1-Meeting-with-FDA-for-IDE196-Confirms-Acceptability-of-Single-Arm-Trial-Design-for-Potential-Phase-2-Registration-Enabling-Study-in-Metastatic-Uveal-Melanoma)

<a id="heading-3.1.3.8.4"></a>

###### 3.1.3.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.3.8.5"></a>

###### 3.1.3.8.5 Safety Results

<a id="topic-3.1.3.8.5-1"></a>

###### Dose-limiting toxicities and declaration of the maximum tolerated doses and recommended dose for expansion

> “First cycle dose-limiting toxicities (DLTs) were observed in 7/38 (18.4%) QD and 2/17 (11.8%) BID patients. Hypotension was the most common DLT, occurring at doses ≥500 mg/day, and manageable with LXS196 interruption and dose reduction.”

Source: [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/)

> “The MTDs were declared at 500 mg QD and 400 mg BID, based on the BLRM and EWOC principles.”
> “Following the BLRM recommendation guided by EWOC and review of all available safety and PK data, the RDE was declared at 300 mg BID (Supplementary Fig. 1).”
> “Of the 55 patients evaluable for MTD/RDE determination, DLTs were observed in nine (16.4%) patients (seven patients treated in the QD schedule and two patients in the BID schedule) (Table 2A). The most common DLT was hypotension (n = 6; 10.9%).”
> “Other DLTs included nausea and vomiting, neutropenia and generalised oedema (one patient each; 1.8%). GI-related DLTs resolved with temporary interruption of study drug and treatment with anti-emetics.”

Source: [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/)

<a id="topic-3.1.3.8.5-2"></a>

###### Hypotension as a dose-limiting toxicity: timing, presentation, and resolution

> “In the QD schedule, hypotension leading to drug interruption and subsequent dose reduction occurred in five patients treated at doses ≥500 mg (two grade 3 events at 500 mg QD, one grade 4 event at 800 mg QD, one grade 4 and one grade 2 event at 1000 mg QD). These events most commonly occurred within 1 to 4 h after the first or second dose and were sometimes accompanied by a transient loss of consciousness with preceding dizziness and sweating.”
> “Most events resolved within minutes, some within 4 h, with an infusion of intravenous fluids and 2 patients experienced recurrence of hypotension with 1 patient requiring further LXS196 dose reduction.”
> “One DLT of grade 3 hypotension was reported in a patient treated at the highest BID dose tested (400 mg BID).”

Source: [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/)

<a id="topic-3.1.3.8.5-3"></a>

###### Adverse events suspected to be related to LXS196 by schedule and at the recommended dose for expansion

| Preferred term | All QD, n = 38, all grades | All QD, grade 3 or higher | All BID, n = 30, all grades | All BID, grade 3 or higher | 300 mg BID (RDE), n = 18, all grades | 300 mg BID (RDE), grade 3 or higher | All patients, N = 68, all grades | All patients, grade 3 or higher |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Participants with at least 1 adverse event, n (%) | “35 (92.1)” | “11 (28.9)” | “28 (93.3)” | “6 (20.0)” | “17 (94.4)” | “2 (11.1)” | “63 (92.6)” | “17 (25.0)” |
| Nausea, n (%) | “26 (68.4)” | “1 (2.6)” | “19 (63.3)” | “0” | “14 (77.8)” | “0” | “45 (66.2)” | “1 (1.5)” |
| Diarrhoea, n (%) | “15 (39.5)” | “0” | “16 (53.3)” | “1 (3.3)” | “11 (61.1)” | “1 (5.6)” | “31 (45.6)” | “1 (1.5)” |
| Vomiting, n (%) | “12 (31.6)” | “1 (2.6)” | “9 (30.0)” | “0” | “7 (38.9)” | “0” | “21 (30.9)” | “1 (1.5)” |
| Alanine aminotransferase increased, n (%) | “7 (18.4)” | “2 (5.3)” | “8 (26.7)” | “2 (6.7)” | “5 (27.8)” | “1 (5.6)” | “15 (22.1)” | “4 (5.9)” |
| Hypotension, n (%) | “8 (21.1)” | “5 (13.2)” | “7 (23.3)” | “1 (3.3)” | “3 (16.7)” | “0” | “15 (22.1)” | “6 (8.8)” |
| Fatigue, n (%) | “10 (26.3)” | “0” | “4 (13.3)” | “0” | “3 (16.7)” | “0” | “14 (20.6)” | “0” |
| Asthenia, n (%) | “6 (15.8)” | “0” | “7 (23.3)” | “0” | “4 (22.2)” | “0” | “13 (19.1)” | “0” |
| Aspartate aminotransferase increased, n (%) | “5 (13.2)” | “2 (5.3)” | “6 (20.0)” | “2 (6.7)” | “3 (16.7)” | “1 (5.6)” | “11 (16.2)” | “4 (5.9)” |
| Dry skin, n (%) | “2 (5.3)” | “0” | “6 (20.0)” | “0” | “4 (22.2)” | “0” | “8 (11.8)” | “0” |
| Rash, n (%) | “3 (7.9)” | “0” | “5 (16.7)” | “0” | “4 (22.2)” | “0” | “8 (11.8)” | “0” |
| Blood creatinine increased, n (%) | “2 (5.3)” | “0” | “5 (16.7)” | “0” | “2 (11.1)” | “0” | “7 (10.3)” | “0” |
| Constipation, n (%) | “4 (10.5)” | “0” | “3 (10.0)” | “0” | “1 (5.6)” | “0” | “7 (10.3)” | “0” |

Source: [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/)

<a id="topic-3.1.3.8.5-4"></a>

###### Grade 3 or higher serious adverse events regardless of relationship, by schedule

| Preferred term | All QD, n = 38 | 300 mg BID (RDE), n = 18 | All BID, n = 30 | All patients, N = 68 |
| --- | --- | --- | --- | --- |
| Participants with at least 1 serious adverse event, n (%) | “7 (18.4)” | “5 (27.8)” | “7 (23.3)” | “14 (20.6)” |
| Hypotension, n (%) | “5 (13.2)” | “0” | “1 (3.3)” | “6 (8.8)” |
| Pneumonia, n (%) | “2 (5.3)” | “1 (5.6)” | “1 (3.3)” | “3 (4.4)” |

Source: [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/)

<a id="topic-3.1.3.8.5-5"></a>

###### Adverse events regardless of relationship, serious adverse events, and tolerability of the two schedules

> “The majority of patients (n = 66; 97.1%) experienced an AE regardless of study drug relationship during the study; 29 (42.6%) of these patients experienced AEs of grade 3/4 (Supplementary Table 2).”
> “The most frequent AEs with LXS196 (all grades, all doses, both schedules) were nausea (n = 48; 70.6%), diarrhoea (n = 37; 54.4%), vomiting (n = 26; 38.2%), fatigue (n = 19; 27.9%), increased alanine aminotransferase (ALT, n = 18; 26.5%), constipation (n = 17; 25%), asthenia (n = 15; 22.1%) and hypotension (n = 15; 22.1%).”
> “The most frequent AEs of grade ≥3, regardless of study drug relationship, were hypotension (n = 6; 8.8%), increased aspartate aminotransferase (AST, n = 5; 7.4%) and increased ALT (n = 4; 5.9%).”
> “Serious AEs (SAEs) were observed in 14 (20.6%) patients, and all were grade 3/4; the most frequent were hypotension (n = 6; 8.8%) and pneumonia (n = 3; 4.4%) (Table 2C). BID appeared to be better tolerated than QD dosing, with fewer treatment-related grade 3/4 AEs and treatment-related SAEs. Grade 3/4 hypotension was more common in the QD versus the BID groups (13.2% versus 3.3%).”

Source: [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/)

<a id="topic-3.1.3.8.5-6"></a>

###### Interruptions and dose reductions as described by the authors

> “Overall, LXS196 was generally well tolerated as a single agent, with the majority of patients not requiring interruption of LXS196 or a dose reduction from their assigned dose level.”

Source: [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/)

<a id="heading-3.1.3.9"></a>

##### 3.1.3.9 Study Limitations

<a id="topic-3.1.3.9-1"></a>

###### Summary

CLXS196X2101 is a nonrandomized, open-label, single-group phase 1 study of LXS196 (darovasertib) as a single agent, without crizotinib. No hypothesis testing was planned and no formal sample size calculation was made; data are presented descriptively. Of the 68 participants, 59 (86.8%) had received prior systemic therapy, and none had received prior tebentafusp. Participants were treated across once-daily doses of 100 to 1000 mg (n = 38) and twice-daily doses of 200 to 400 mg (n = 30), and 18 were evaluable at the recommended dose for expansion of 300 mg twice daily. Tumour response was assessed locally per RECIST v1.1. The ORR denominator differs between the text (6 of 66 evaluable participants, 9.1%) and the results table, which includes 2 participants without post-baseline assessment in a denominator of 68; the 95% CI of the 6-month PFS rate in all participants is 19.1 to 40.4 in the text and 19.1 to 29.2 in the table. Pharmacodynamic analysis was not performed on tumour samples from the twice-daily schedule, the authors note that the C1D15 biopsy timepoint might be too late to observe transient changes, and the sequencing panel did not include CYSLTR2 and PLCB4. The combination part with HDM201 was terminated early for business reasons. No quality-of-life or patient-reported outcome results were reported; the registry outcomes cover dose-limiting toxicities, adverse events, dose modifications, ORR, PFS, and pharmacodynamics.

Source: [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/); [ClinicalTrials.gov NCT02601378](https://clinicaltrials.gov/study/NCT02601378)

<a id="topic-3.1.3.9-2"></a>

###### Exploratory phase 1 design without formal statistical testing

> “Owing to the exploratory nature of this phase I study, formal statistical tests were not planned to be performed.”

Source: [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/)

<a id="topic-3.1.3.9-3"></a>

###### Genes not covered by the sequencing panel

> “The genes CYSLTR2 and PLCB4 were not included in the sequencing panel.”

Source: [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/)

<a id="topic-3.1.3.9-4"></a>

###### Timing of on-treatment biopsies for pharmacodynamic assessment

> “There are several possible explanations for the lack of correlation between reductions in pMARKCS/pPKCd and clinical activity. One possibility is that the PKC signalling pathway is highly sensitive to LXS196 exposure, and a C1D15 timepoint might be too late to observe transient changes.”

Source: [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/)

## Related pages
- [Darovasertib (IDE196): First-line metastatic uveal melanoma, in combination with crizotinib](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Terms and abbreviations](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/terms-and-abbreviations.md)
- [Darovasertib (IDE196): First-line metastatic uveal melanoma, in combination with crizotinib](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/executive-summary) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/executive-summary.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Product information and disease description](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Economic information and modeling report](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/economics) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/economics.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: References](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/references) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/references.md)
